Document:

Exhibit 10.31.1

 

***
TEXT OMITTED AND SUBMITTED SEPARATELY

PURSUANT TO CONFIDENTIAL TREATMENT REQUEST

UNDER 17 C.F.R. SECTIONS 200.80(b)(4) AND 230.406

 

AMENDMENT TO SUPPLY AGREEMENT

 

BY AND BETWEEN

 

BAYER HEALTHCARE LLC AND TALECRIS BIOTHERAPEUTICS, INC

 

This
Amendment is entered into as of June 30, 2008 and amends the Supply
Agreement by and between Talecris Biotherapeuties, Inc. (“Talecris”)
and Bayer Healthcare LLC (“Bayer”) dated March 31, 2005 (“Agreement”).

 

WHEREAS,
The Parties entered into the Agreement for the supply by Talecris to Bayer of PPF
(as defined in the Agreement); and

 

WHEREAS,
The term of the Agreement may be extended until December 2012, but the Parties
desire to amend the Agreement to allow for further extensions of the said term.

 

NOW,
THEREFORE, for and in consideration of the premises and the mutual covenants
contained herein, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties hereby agree as
follows:

 

1.
Defined Terms. Capitalized terms used in this Amendment shall have the
meanings ascribed to such terms in the Agreement.

 

2.
Term. Article I of the Agreement shall be replaced by the
following:

 

“This
Agreement shall have an initial term commencing on the Effective Date and
terminating on December 31, 2008 (“Initial Term”)
unless earlier terminated as provided in Article 10 below. The Initial Term
may be renewed for two consecutive two (2) year periods, followed by two (2) consecutive
one (1) year periods (“Extended Term”), all at the option of Bayer,
provided that Bayer gives Supplier at least one (1) year’s written notice of
its intent to renew prior to the commencement of each term With the mutual
agreement of both parties an additional 1 year agreement may be provided, (“Final
Extended Term”) provided that Bayer notified Talecris 15 months in advance of
the commencement of the extended term.

 

3. Required Quantities - For the “Extended Term and
the Final Extended Term the Required Quantity of PPF provided must be not less
than [***] and not more than [***] annually.

 

Except
as expressly amended in the Amendment the Agreement shall remain in full force
and effect.

 

IN
WITNESS WHEREOF, the Parties have caused this Amendment to be signed by their
respective officers thereunto duly authorized, all as of the date first written
above.

 

 

	
  TALECRIS BIOTHERAPEUTICS,
  INC.

  	
   

  	
  BAYER HEALTHCARE LLC

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Mary Kuhn

  	
   

  	
  By:

  	
  /s/ Joerg Heidrich

  
	
   

  	
   

  	
   

  
	
  Name: Mary Kuhn

  	
   

  	
  Name: Joerg Heidrich, SVP

  
	
   

  	
   

  	
   

  
	
  Title: SVP, Operations

  	
   

  	
  Title: Global Head Product
  Supply Biotech

  
	
   

  	
   

  	
   

  
	
  AG 09/11/2008

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  CONFIDENTIAL

  	
   

  	
   

  
					

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

1Exhibit 10.34

 

***  TEXT OMITTED AND SUBMITTED SEPARATELY

PURSUANT TO
CONFIDENTIAL TREATMENT REQUEST  

UNDER 17 C.F.R.
SECTIONS 200.80(b)(4) AND 230.406

 

PROLASTIN DIRECTSM

AMENDED AND RESTATED
SERVICES AGREEMENT

 

THIS
AMENDED AND RESTATED SERVICES AGREEMENT (“Agreement”) is made and entered into
as of this 1st day of January, 2009 (the “Effective Date”) by and between
TALECRIS BIOTHERAPEUTICS, INC., a Delaware corporation (“Talecris”), and
CENTRIC HEALTH RESOURCES, INC., a Delaware corporation (“CHR”).  Talecris and CHR may each be referred to
herein as a “party” or collectively as the “parties”.

 

WHEREAS,
the parties entered into that certain Services Agreement dated as of August 25,
2005, as amended (the “Original Agreement”), with an initial term commencing August 25,
2005 and continuing through December 31, 2008 by an extension agreed to by
the parties;

 

WHEREAS,
the parties hereto desire to amend, supplement, restate and supersede the
Original Agreement, all as hereinafter provided;

 

WHEREAS,
Talecris is in the business of manufacturing prescription drugs as described in
this Agreement; and

 

WHEREAS,
CHR, either directly or through subcontractors, is in the business of
furnishing clinical and administrative pharmacy services (including, but not
limited to, prescription filling, delivery of prescription drug and ancillary
products, pharmacy benefits management services and related home infusion
services and reimbursement services) as described in this Agreement; and

 

WHEREAS,
Talecris desires to have CHR perform such services from time to time;

 

WHEREAS,
the parties desire to agree upon the terms and conditions upon which such
services shall be provided.

 

NOW,
THEREFORE, in consideration of the mutual agreements and set forth herein, and
for other good and valuable consideration, the receipt and sufficiency of which
is acknowledged, Talecris and CHR agree as follows:

 

1.             DEFINITIONS. 
Capitalized terms not otherwise defined shall have the meanings set
forth as follows:

 

1.1           “Adverse Event” shall mean any
adverse change in health or side-effect associated with the use of any drug in
a human, whether or not considered drug-related.

 

1.2           “Affiliate” shall mean any person,
individual, corporation or other business entity that either directly or
indirectly, through one or more intermediaries, owns, is owned by, or is under
common ownership with a party to this Agreement, where “own,” “owned” or
“ownership” refers to (i) direct or indirect possession of at least fifty
percent (50%) of the outstanding voting securities of a corporation or a
comparable ownership in any other type of entity; or (ii) the actual
ability of an entity, person or group to control and direct the management of
the person or entity, whether by contract or otherwise.

 

 

1.3           “Business Day” shall mean any day
other than a day which is a Saturday, Sunday or federal bank or federal
government holiday in the United States of America.

 

1.4           “Exit Assistance Services” shall
mean those services described in the Exit Plan to be performed by CHR for the
purpose of transitioning the Services to Talecris or to a successor service
provider chosen by Talecris upon the expiration or termination of this
Agreement.

 

1.5           “Exit Plan” shall mean the written
plan agreed by the parties pursuant to Section 2.4 for provision of Exit
Assistance Services by CHR.

 

1.6           “IG” means immune globulin.

 

1.7           “Patient” shall mean a patient
registered in the Program.

 

1.8           “Payor” shall mean the Patient’s
third party payor responsible for reimbursement of covered charges to Prolastin
Directs®.

 

1.9           “Products” shall mean Talecris’
Alpha-1 products, including, without limitation, Prolastin® and any successor,
replacement or alternative products to Prolastin®, or any therapeutic
equivalent or derivatives thereof.

 

1.10         “Program” shall mean the Prolastin
Directs® program for furnishing Prolastin® to Patients who register with the
Prolastin Directs® program as set forth in Exhibit A, attached
hereto and incorporated herein by reference.

 

1.11         “Services” shall mean the services
provided by CHR under this Agreement, including the delivery, home infusion,
and pharmacy services set forth in Exhibit A.

 

1.12         “Standards of Specialty Pharmacy”
shall mean all federal, state and local laws, regulations, rules and
binding guidance with respect to specialty pharmacies.

 

1.13         “Talecris Consigned Inventory”
shall mean the Products delivered on a consignment basis to, and accepted by,
CHR into inventory for provision to Patients under the terms of this Agreement.

 

1.14         “Term” shall mean that Initial
Term and all Renewal Terms, as defined in Section 9.1.

 

2.             SERVICES.

 

2.1           Engagement.  Talecris
hereby engages CHR as an independent contractor to render, and CHR agrees to be
engaged to render, the Services on the terms and conditions set forth
herein.  Services provided to Patients
shall be provided upon the request of a Patient or his or her legal
representative, in accordance with and upon receipt of a valid physician’s
prescription.

 

 

2.2           Subcontractors. 
Unless otherwise required by law, CHR shall not subcontract the Services
in whole or in part to any third party other than AlphaNet, Inc., without
the prior written approval of Talecris, which approval shall not be
unreasonably withheld, delayed or conditioned. 
In the event Talecris elects to approve CHR’s proposed use of a
subcontractor to perform Services hereunder, CHR shall remain liable and be
responsible for the action, inactions and performance of all obligations
performed by subcontractor to the same extent as if such obligations were
performed by CHR employees and, for purposes of this Agreement, such
subcontracted services shall be deemed Services performed by CHR.

 

2.3           Additional Services. 
From time to time Talecris may request implementation of “new” or
“additional” services (“Additional Services”) that are not included in the
Services contemplated by this Agreement. 
In the event Talecris requests CHR to provide such Additional Services,
CHR will prepare a written estimate of the staff time, materials and other
costs for such Additional Services for review by Talecris.  If Talecris desires to CHR to proceed with
such Additional Services, the parties will enter into a written agreement
setting forth the Additional Services to be provided and the compensation to be
paid by Talecris to CHR for such Additional Services.  Unless otherwise agreed by the parties, CHR’s
staff time will be billed at an hourly rate of $100 per hour and materials and
other items will be billed on a cost basis; Talecris will pay CHR for 50% of
the estimated cost of such Additional Services at initiation of the project and
the remaining balance of the cost of such Additional Services will be paid by
Talecris to CHR promptly at project completion. 
Transitions to new versions of Product are not considered “Additional
Services” that are eligible for additional fees.

 

2.4           Exit Plan.  The parties
acknowledge that they have agreed upon an Exit Plan, Upon the reasonable
request of a party, the parties will review and consider, in good faith,
whether the Exit Plan should be modified and, if a party believes that
modifications are necessary or appropriate, the parties will use commercially
reasonable efforts to reach agreement, in writing, on modifications to the Exit
Plan.  The Exit Plan shall include,
without limitation, a schedule of transition of the Services from CHR to
another contractor or to Talecris.  The
Exit Plan shall set forth the manner and timing in which CHR shall provide Exit
Assistance Services, including without limitation: (a) making available on
a commercially reasonable basis, necessary personnel and resources to
facilitate the transition, (b) providing such interim Services as are
necessary to successfully complete the transition, and (c) providing
training, documentation and other materials necessary to enable Talecris, or
its designee, to assume responsibility for the Services, as mutually agreed in
writing by the parties.  In the event
this Agreement is terminated by Talecris at expiration of its then current Term
or for reasons other than pursuant to Section 9.3.3 due to a material
breach by CHR, Talecris will pay CHR the reasonable costs associated with the
transitioning of Patients to the new program manager(s).

 

2.5           Talecris, CHR and Subcontractor
Qualifications.  When received, each of Talecris and CHR shall
maintain all provider or supplier agreements and numbers necessary for the
submission by CHR of claims to Payors. 
Each of Talecris and 

 

 

CHR shall make
available to the other upon reasonable request documentation of all of its
applicable federal, state and professional licenses, certificates, and provider
or supplier agreement numbers.  With
respect to approved subcontractors, CHR shall require that such subcontractors
have and continue to maintain all material licenses and certificates applicable
to the Services to be provided by such subcontractors.  Talecris shall require that its
subcontractors engaged in the manufacture of Products have and continue to
maintain all material licenses and certificates applicable to the manufacture
of Products.  CHR and Talecris shall use
best efforts to ensure that their respective subcontractors described in this Section 2.5
are not excluded from participation in federal health care programs (as defined
in 42 U.S.C. Section 1320a - 7b(f)) (“Federal Health Care Programs”).

 

2.6           Employee and Independent Contractor
Qualifications.  Personnel assigned by CHR for the performance
of the Services shall be fully trained, competent and skilled.  CHR shall (i) maintain at all times
adequate personnel to perform the Services, and (ii) ensure that all such
staff are not excluded from participation in Federal Health Care Programs.  CHR shall implement and maintain a program to
verify that the employees and independent contractors utilized by CHR in connection
with the provision of the Services are not excluded from participation in
Federal Health Care Programs.  CHR shall
make available to Talecris upon Talecris’ reasonable request documentation of
all applicable licenses and certificates prior to execution of this Agreement
and throughout the term of this Agreement. 
CHR shall obtain appropriate assurances that persons employed or engaged
by any subcontractors to furnish Services hereunder shall have and maintain
such applicable licenses and certifications. 
CHR shall, at CHR’s expense, perform appropriate criminal background
screening and reference checks prior to hiring any employee or engaging any
independent contractor.  CHR shall
adequately train all of its personnel associated with the Program in the
applicable diseases and treatments, as well as in the provisions of its
Standard Operating Procedures (the “SOPs”).

 

2.7           Compliance with Law and Policies. 
Talecris shall provide Product to CHR and CHR shall provide the Services
in accordance with applicable state and federal laws and regulations.  With respect to its subcontractors hereunder,
each of Talecris and CHR shall require that such subcontractors provide
Services hereunder in accordance with applicable state and federal laws and
regulations.

 

2.8           Standard Operating Procedures.  During
the Term, CHR shall maintain competent and trained staff as required in order
to meet current and anticipated Patient requirements.  CHR shall modify its SOPs in order to satisfy
the reasonable policies and procedures of Talecris that are furnished, in
writing, to CHR at least sixty (60) days prior to their effective date (or the
effective date of any change in an existing policy or procedure) and that are
not objected to by CHR (the “Talecris Policies”).  In the event of any conflict or inconsistency
between a provision of this Agreement and provision of a Talecris Policy, the
provision of this Agreement will govern and control.  CHR shall maintain minimum operational
standards as agreed by the Parties and set forth in this Agreement and 

 

 

the SOPs.  CHR shall develop any required additional
SOPs for approval by Talecris, which approval shall not be unreasonably
withheld, delayed or conditioned.  CHR
shall operate the Program in accordance with such approved SOPs.

 

2.9           Security and Security Audits. 
CHR shall make all necessary upgrades to its facility in order to
satisfy Talecris’ reasonable needs and the Standards of Specialty Pharmacy and
all other applicable federal, state and local laws and regulations.  A qualified third party shall, at CHR’s expense,
conduct a complete security assessment (the “Security Assessment”).  CHR shall provide the results of the Security
Assessment to Talecris.  CHR shall bear
all costs associated with complying with the recommendations set forth in the
Security Assessment and Talecris’ reasonable needs.  Talecris will have the right to perform
audits within the facility and pharmacy areas. 
In addition, CHR will establish and document procedures reasonably
acceptable to Talecris to ensure the physical security of the premises and
products related to the Services, as well as the security and confidentiality
of information and intellectual property used in connection with the
Services.  CHR shall provide such
documented procedures to Talecris upon Talecris’ reasonable request.

 

2.10         Safety Standards. 
CHR shall comply with all applicable safety requirements and standards
mutually agreed by the Parties and/or required by applicable laws.  CHR will maintain current safety procedures
and train all personnel to comply with such standards.

 

2.11         Quality Control. 
CHR shall comply with all applicable quality control standards and
requirements agreed by the Parties.  In
addition, CHR shall maintain a continuous quality improvement process and will
share this process with Talecris for review and comment.

 

2.12         Information Database. 
CHR shall maintain a secure database of all Patient information.  Unless otherwise agreed to in writing by the
parties, prior to disclosing any Patient information to Talecris, CHR shall
first de-identify such information in accordance with applicable standards set
forth in privacy rules promulgated pursuant to the Administrative
Simplification provisions of the Health Insurance Portability and
Accountability Act of 1996 (“HIPAA”). 
CHR shall make available to Talecris, upon the request of Talecris,
aggregated de-identified patient information related to Patients.

 

2.13         Change in Services. 
In the event either Party wishes to make changes to the Services, which
may involve: (i) an increase or decrease in the number of personnel
required; (ii) a material change in the scope of Services; or (iii) other
changes which may affect the fees and/or schedule for performance of Services,
such party will notify the other party of such desire and provide the other party
with a written proposal of the changes and reasons therefor.  During the sixty (60) day period following
the giving of such notice, the parties shall work expeditiously and in good
faith to reach agreement, in writing, on the changes, if any, to be made to
this Agreement.

 

 

2.14         Benchmarking. 
CHR is committed to “Best in Class” service.  To ensure delivery of such service, Talecris
shall have the right, at its expense, to have the performance of, or the costs
and expenses for, all or a portion of the Services reviewed by an independent
industry-recognized benchmarking service provider organization with
demonstrated benchmarking expertise reasonably acceptable to CHR (the
“Benchmarker”) in order to evaluate the efficiency, effectiveness and
productivity of CHR’s performance of the Services and whether the costs and
expenses are competitive in the industry. 
The Benchmarker shall be selected by Talecris and approved by CHR, such
approval not to be unreasonably withheld, conditioned or delayed.  Talecris shall have the right to disclose the
terms of this Agreement to the Benchmarker in connection with obtaining such
review.  CHR shall cooperate with the
Benchmarker, including, as appropriate, making available knowledgeable
personnel and pertinent documents and records. 
The Benchmarker shall be subject to a confidentiality agreement similar
to the confidentiality provisions set forth in this Agreement.  Each Party shall be provided a reasonable
opportunity to review, comment on and request changes in the Benchmarker’s
proposed findings.  Following such review
and comment, the Benchmarker shall issue a final report of its findings and
conclusions.  If, in the final report of
the Benchmarker, the benchmarked Services are not in the top ten percent (10%)
of the representative sample (viewed from the reasonable perspective of
Talecris), then CHR shall within thirty (30) days after issuance of the
Benchmarker’s final report, either: (a) provide Talecris with written
notice that CHR accepts such final report; or (b) provide Talecris with
written objections to such final report. 
If no written acceptance or objections are received within such thirty
(30) day period, the final report shall be deemed accepted.  If CHR accepts such final report, CHR
promptly shall develop a plan and schedule, subject to the approval of
Talecris, which approval shall not be unreasonably withheld, delayed or
conditioned, to bring CHR within the top ten percent (10%) in a reasonable
period of time.  CHR then shall implement
the plan and achieve the top ten percent (10%) in the designated period of
time.  If CHR does not accept the report
and instead provides written objections, Talecris and CHR shall use
commercially reasonable efforts to resolve such objections.  If Talecris and CHR cannot resolve such
objections within fifteen (15) days following Talecris’ receipt of such
objections, then the Parties shall resolve the dispute in accordance with the
terms of Section 21.

 

3.             PRODUCT CONSIGNMENT, DISTRIBUTION AND
ADMINISTRATION.

 

3.1           General.  Talecris
shall furnish Product to CHR on a consignment basis for dispensing to Patients.

 

3.2           Transfer of Title Risk of Loss. 
Risk of loss with respect to Talecris Consigned Inventory shall pass
from Talecris directly to CHR when CHR accepts Talecris Product as evidenced by
a delivery receipt signed by CHR.  CHR
shall have two (2) Business Days after delivery in which to accept or
reject the Product.  CHR shall not take
title to any Product.  Title to Talecris
Consigned Inventory shall pass directly from Talecris to the Patient, hospital
or physician at the time the Products are received by such Patient, hospital or
physician.  CHR shall utilize a 

 

 

system that will
record receipt, inventory levels, and shipments on a Product-by-Product
basis.  CHR shall provide to Talecris
month-end reports reflecting such activity for the month and the month-end
inventory balance.  Upon Talecris’
reasonable request, CHR will make daily inventory status information available
to Talecris.  Upon the termination or
expiration of this Agreement, CHR shall return to Talecris all Talecris
Consigned Inventory in the possession of CHR, in accordance with proper
handling instructions.  Such return will
be at the expense of Talecris.

 

3.3           Damaged Products. 
CHR shall be responsible for the cost of any Talecris Consigned
Inventory that is damaged as a result of CHR actions, including, without
limitation, improper storage, damage during packing, mishandling of Product,
failure to label, pack, ship, or store Products in compliance with labeled
manufacturer’s storage requirements, or for theft or shrinkage of Product that
occurs while in CHR’s facilities or possession and control.  CHR also shall be responsible for the cost of
any Talecris Consigned Inventory that is: (i) shipped to the wrong address
by CHR, or (ii) not packaged or shipped according to the mutually agreed
upon shipping procedure.  Payment to
Talecris by CHR for Product that is lost or damaged while in CHR’s possession
or care will be based on the then current wholesale price for the Product.  CHR is not responsible for the cost of
Product returned by Patients.

 

3.4           Ownership of Products. 
All Products consigned to CHR by Talecris hereunder will be and remain
at all times under and subject to the ownership of Talecris until such Products
are sold to Patients.  CHR will promptly
execute and deliver to Talecris such documents and take such action as Talecris
may reasonably request in order to fully protect Talecris’ interest in the
Talecris Consigned Inventory in accordance with the Uniform Commercial Code as
enacted in North Carolina, or other applicable law, including without
limitation, the filing of financing and continuation statements.  CHR hereby authorizes Talecris or its agents
to execute on its behalf any and all necessary documents to affect any such
filings (including the filing of any such financing or continuation statement)
without further authorization of CHR.  As
it may be required by applicable law, CHR grants a security interest to
Talecris, as a secured party, in any and all right, title and interest which
CHR now or may hereafter have in the Talecris Consigned Inventory.

 

3.5           Physical Inventory. 
Upon Talecris’ reasonable request, but no less than once per year, CHR
shall take and report a physical inventory of the Talecris Consigned
Inventory.  Such request shall be honored
in a timely fashion.  Talecris will
reimburse CHR for its reasonable out-of-pocket costs incurred to take such
physical inventory.  Talecris may, in its
sole discretion and at its sole cost, elect to either observe the physical
inventory being conducted or be represented by a third-party accounting firm.

 

3.6           Timely Shipment of Products to Patients. 
Talecris shall use commercially reasonable efforts to ensure that CHR
has adequate inventory of Products to respond to Patient demands.  CHR shall ensure that such inventory is
dispatched 

 

 

to Patients in a
timely manner.  For all Products
available in the Talecris Consigned Inventory and available for shipment, CHR
will ensure that shipment to Patients are made within one (1) Business
Day, except as a Patient otherwise directs, or as soon as practicable, after
acceptance of the order by CHR, provided that CHR has: (i) obtained proper
authorization therefor from the Patient’s physician; (ii) obtained all
information necessary in order to complete the Intake Form and insurance
verification form in a manner satisfactory to CHR; (iii) completed the
requirements set forth in Section 2 and Exhibit A; (iv) received
proper prior authorization from the applicable Payor; and (v) retained the
services of appropriately credentialed nursing services providers or other
subcontractors as necessary to provide such Services, as applicable.

 

3.7           Dispensing of Talecris Consigned
Inventory.  Unless otherwise agreed by the Parties, in
addition to the other requirements of this Section 3 and Exhibit A
applicable to Talecris Consigned Inventory, CHR shall dispense Products from
the Talecris Consigned Inventory to Patients on a first-come, first-served
basis after prior authorization is received.

 

3.8           Regulatory Action. 
CHR shall timely advise Talecris in writing of any regulatory action
directly related to CHR’ s shipping of Products from its facilities, including
without limitation, any government agency inspection and subsequent remedial
action taken by CHR in response.  CHR
shall also timely advise Talecris in writing of any problems at its facilities
related to the Products, including without limitation, fulfillment errors, and
any other action or omission that did, or could reasonably be expected to,
adversely affect the safety, efficacy or salability of any of the Products,
together with a statement of all corrective or remedial action taken.

 

3.9           Government Inspections. 
If the U.S. Food and Drug Administration (“FDA”) or any other
governmental authority (a “Regulatory Authority”) conducts an inspection at
CHR’s facility, seizes any Product and/or any of CHR’s materials, requests a
recall of any Product, or notifies CHR of any violation or potential violation
of any applicable law, CHR shall notify Talecris immediately, and CHR shall
take such actions as may be reasonably instructed by Talecris and are in
compliance with applicable law.  As
applicable, CHR shall promptly send any reports relating to such inspections,
recalls or violations or potential violations of law to Talecris.  In the event that any Regulatory Authority
makes any request with respect to, but does not seize, the Product in
connection with any such inspection, CHR, as the case may be (i) shall promptly
notify Talecris of such request, (ii) if possible, shall satisfy such
request only after receiving Talecris’ approval, which approval shall not be
unreasonably withheld, delayed or conditioned (iii) shall follow any
reasonable procedures required by Talecris in responding to such request and (iv) shall
promptly send any samples of the Product requested by the Regulatory Authority
to Talecris.

 

3.10         Recall.  In the event (i) any
Regulatory Authority issues a request, directive or order that the Products be
recalled, or (ii) a court of competent jurisdiction orders such a recall,
or (iii) Talecris reasonably determines that the Products should be 

 

 

recalled for any
reason, the Parties shall take all appropriate corrective actions.  CHR shall be responsible for all the expense
of recalling the Products in the event that the recall relates to CHR’s failure
to store or distribute the Products properly or failure to perform its
obligations under this Agreement.  Except
to the extent that the reason for the recall relates to CHR’s failure to store
or distribute the Products properly or failure to perform its obligations under
this Agreement, Talecris shall be responsible for all the expense of recalling
the Products (e.g., shipping charges, man-hours spent arranging and
coordinating recall).  Talecris will be
responsible for all returns and all aspects of any recall except as provided
herein.  Procedures for handling returns
will be covered by communications from CHR to Talecris.

 

3.11         Patient Complaints. 
CHR shall notify Talecris in writing within four (4) days of
initial receipt of any information CHR receives regarding the safety or
efficacy of the Product (except with respect to Adverse Events, which shall be
governed by Section 3.12 below). 
CHR shall notify Talecris of any complaint or investigation relating to
the Product promptly upon receipt by CHR; provided that all complaints
concerning suspected or actual Product tampering, contamination or mix-up
(e.g., wrong ingredients) shall be delivered to Talecris within twenty-four
(24) hours of receipt.  CHR shall provide
all assistance reasonably requested by Talecris in investigating customer
complaints regarding the Product that, in Talecris’ reasonable opinion, are
related to or arise from CHR’s distribution of the Product or other performance
of the Services.  Talecris shall
determine and notify CHR of the appropriate response to Patients’ complaints,
and CHR shall be responsible for providing such response to all Patients and
the record keeping relating thereto.

 

3.12         Adverse Events. 
With respect to any Product, CHR shall notify Talecris in accordance
with the applicable SOP promptly following its receipt of information of a
possible Adverse Event.  To the extent an
Adverse Event of which CHR becomes aware implicates the manufacture or
distribution of the Product, CHR shall promptly inform Talecris of such Adverse
Event and shall disclose to Talecris any information it has regarding that
Adverse Event, The parties shall investigate all reports of an Adverse Event in
order to assure the safety and efficacy of the Products.  The parties shall act promptly and shall
cooperate fully in such investigations.

 

4.             INDEPENDENT CONTRACTOR.

 

4.1           General.  In rendering
Services hereunder, CHR shall act as an independent contractor and not as an
employee, agent or authorized representative of Talecris, Although CHR will
receive generalized instruction from Talecris as to the performance of Services
hereunder, Talecris will not control or supervise the specific methods to be
used or the sequence of tasks to be performed by CHR in the execution of its
duties hereunder.  CHR shall have no
authority to make or influence managerial or policy decisions of Talecris, nor
to bind Talecris to any contract, agreement or obligation.  The acts of CHR shall in no way constitute
the acts of Talecris, and CHR shall not represent to any third party that CHR
has any 

 

 

express or implied
authority to bind Talecris to any contract, agreement or obligation.

 

4.2           Income Taxes. 
No amounts payable by Talecris under this Agreement shall be considered
salary for pension and incentive compensation purposes.  Furthermore, no CHR personnel shall be
entitled to any fringe or supplemental benefits of regular employees of
Talecris.  CHR shall bear all
responsibility and liability for the payment of all federal, state and local
income taxes due on money received from Talecris under this Agreement and
filing all appropriate tax returns and other forms with respect thereto.  Moreover, CHR shall be solely responsible for
(i) payment of all compensation to its employees, (ii) all health
and/or disability insurance, retirement benefits, and other welfare or pension
benefits to which its employees may be entitled and (iii) all employment
taxes and withholding with respect to its employees.  CHR agrees to indemnify and hold Talecris,
its officers, directors, employees, shareholders and agents harmless from and
against any and all such liabilities or claims including, but not limited to,
interest assessed or penalty and reasonable attorneys fees incurred, arising
from CHR’s failure to comply with its obligations under this Section of
the Agreement.

 

5.             COMPENSATION.

 

5.1           Monthly Invoicing. 
Unless otherwise agreed in writing, by the parties, during the Term, CHR
shall invoice Talecris on a monthly basis for the Services provided during the
previous month, according to the pricing set forth in Exhibit B and
additional payments set forth in Exhibit C, attached hereto and
incorporated herein by reference (the “Pricing Schedule”), CHR shall maintain
adequate records to support hours claimed and shall make such records available
to Talecris upon reasonable request.

 

5.2           Payment Terms. 
Payment is due forty-five (45) days from the date of each invoice.

 

5.3           Taxes.  Talecris
shall bear all responsibility and liability for all sales, use, excise,
services, consumption, and other taxes and duties associated with the provision
of Services to Patients.

 

6.             EXCLUSIVITY.

 

6.1           Alpha-1 Programs.

 

6.1.1       CHR and its affiliates shall not
administer any other manufacturer-sponsored pharmacy-direct program related to
any other Alpha-1 replacement therapy or distribute any wholesale product
related to Alpha-1 replacement therapy other than Products without prior
written agreement of Talecris, except that, in a medical emergency in which a
medical doctor determines that a Patient requires product other than Products,
the Parties may agree to allow CHR to purchase and distribute such other
prescribed 

 

 

product to such Patient,
such agreement not to be unreasonably withheld, delayed or conditioned.

 

6.1.2       Talecris may not sell Product to an
independent wholesale distributor, independent specialty pharmacy or
independent home health company, other than through CHR pursuant to this
Agreement, without the prior written approval of CHR.  For purposes hereof, a distributor, pharmacy,
or home health company is “independent” if it is not does not serve a single
health plan or network of health plans exclusively and is not wholly-owned by a
health plan or network of health plans.

 

6.1.3       Talecris may not distribute Product to an
individual patient, hospital, infusion clinic or company, or other health care
provider with the intent to sell Product, other than through CHR pursuant to
this Agreement or as otherwise agreed to by the parties as stated in this
Agreement, without the prior written approval of CHR.  Notwithstanding the foregoing, Talecris may
sell and distribute Product directly to individual researchers or academic
institutions for the purposes of basic or clinical research.

 

6.1.4       [***] 
With respect to each such contract with a [***], Talecris agrees to use
commercially reasonable efforts to not modify or adversely affect the Services
of CHR typically provided with respect to the Product for individuals covered
by such [***] as stated herein.  [***]

 

6.1.5       In the event that Talecris cannot meet
patient demand for Product, whether by force majeure or otherwise, Talecris may
purchase Alpha-1 augmentation products from other manufacturers or distributors.  If Talecris purchases other Alpha-1 products
for distribution through the Prolastin Direct program, Talecris will pay CHR
the Base Fee set forth on Exhibit B to handle and distribute such
other products.  If Talecris does not
purchase comparable Alpha-I products in the event of a shortage of Product, CHR
may purchase other Alpha-1 augmentation products and sell that product to
patients and Payors after providing 30-days written notice to Talecris, when
possible.  When sufficient Product becomes
available, CHR will resume using Talecris as its sole supply source for all
Patients. The Base Fee will not apply to, or be charged to Talecris by CHR for
any Alpha-1 product (other than the Product) bought and sold by CHR.  Talecris shall not be liable to CHR for any
consequential or other damages as a result of Product shortages.

 

6.1.6       If the total Alpha-1 Patient volume
served by CHR through the Program drops by [***] or more over any 12-month or
shorter period, CHR may terminate the provisions of Sections 6.1.1 and 9.4.5 by
giving at least thirty (30) days prior written notice to Talecris; in which
case, Sections 6.1.1 and 9.4.5 will no longer apply to CHR and Sections 6.1.1
and 9.4.5 will be of no further force and effect.  If CHR exercises its rights under this Section 6.1.6
and then enters into a written agreement with another 

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

manufacturer to
distribute its Alpha-1 product(s), the provisions of Sections 6.1.2 and 6.1.3
will no longer apply to Talecris and Section 6.1.2 and 6.1.3 will be of no
further force and effect.

 

6.2           Other Talecris Programs.

 

6.2.1        IG.  Talecris
shall make available a minimum of [***] grams of Gamunex® per month for direct
to Patient distribution in the Gamunex® direct program (“IG Program”).  Except as otherwise agreed by the parties in
writing, the term “Services” as used in this Agreement shall be deemed to
include services provided in connection with the 1G Program, the term
“Products” as used in this Agreement shall be deemed to include IG products
supplied by Talecris to CHR and the term “Patients” shall be deemed to include
patients registered in the 1G Program, provided that Exhibits A, B and C of
this Agreement shall not apply to the IG Program, All information, data and
materials relating to the IG program will be segregated from all information,
data and materials relating to the Program and all other health management
programs conducted by CHR.  The fees to
be paid by Talecris to CHR for its Services provided in connection with the IG
Program are set forth on the Pricing Schedule (Exhibit B), and will
be invoiced and paid in accordance with Section 5.

 

6.2.2        Other Products.  To the extent
that the Parties contract for programs for other Talecris products, such
programs will be performed on an exclusive basis under substantially similar
terms, with such mutually acceptable changes as are required by the differences
in the programs, and all information, data, materials and service personnel
relating to such additional program(s) will be segregated from all
information, data, materials and service personnel relating to the Program and
the IG Program.

 

6.3           Distribution of Products. 
CHR shall be the sole distributor of Product in the United States,
subject to any requirement under the Veteran’s Health Care Act of 1992 that
Talecris may furnish Products directly to government purchasers.  Special circumstances may arise where mutual
consent between Talecris and Centric will allow for modification to this Section in
accordance with Section 24.  CHR
shall be deemed an Authorized Distributor of Record (“ADR”).

 

7.             BUSINESS ASSOCIATE

 

7.1           The parties anticipate that, in the
future, Talecris may perform, as a business associate, certain services for or
on behalf of CHR, a covered entity under HIPAA, which services may involve the
receipt or use of certain “protected health information”.  If that will occur, the parties must first
mutually agree, in writing, upon the services to be performed by Talecris for
or on behalf of CHR that require Talecris to use and receive “protected health
information” (PHI).  The parties also must
agree on the specific data elements of PHI that will be disclosed to and used
by Talecris in order to provide such services. 
In no event will 

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Talecris have access to patient names and street addresses.  After reaching agreement, Talecris must sign
a business associate agreement (“CHR-BAA”) with CHR that describes such
services and data elements.  PHI covered
under the CHR-BAA will be restricted to designated Talecris employees
(specifically named in CHR-BAA, with new names to be mutually agreed upon).  Information that Talecris designated
employees access under the CHR-BAA may not be used for the purposes of
marketing to individual patients or for any other purpose, except as expressly
set forth in the CHR-BAA.  Each Talecris
employee covered under the CHR-BAA must successfully complete training programs
designated by CHR under the CHR-BAA.  Any
breach of the CHR-BAA by Talecris that remains uncured for 10 business days
will be considered a material breach of both the CHR-BAA and this
Agreement.  In the CHR-BAA, Talecris will
agree to indemnify CHR and hold harmless CHR (and defend CHR, if requested)
from all liabilities (including reasonable attorneys’ fees) arising out of
Talecris’ receipt, use or disclosure of PHI. 
In the event of a change in ownership of Talecris, the CHR-BAA will
terminate and CHR will cease providing PHI to Talecris until a new CHR-BAA is
agreed to between CHR and Talecris and/or its successors.

 

8.             [***] PROGRAM

 

8.1           The parties agree to establish a [***]
pilot program in accordance with the terms in Exhibit D attached
hereto and incorporated herein by this reference.

 

9.             TERM AND TERMINATION.

 

9.1           Term.  This
Agreement shall begin on the Effective Date and shall continue until December 31,
2013 (the “Initial Term”), unless earlier terminated by either party as
hereinafter provided.  After the
expiration of the Initial Term or any “Renewal Term” (as hereafter defined),
this Agreement will renew for successive terms of two-year each (each a “Renewal
Term”) if agreed to in writing by the parties.

 

9.2           Termination. 
During the Initial Term, either party can terminate this Agreement only
for cause, pursuant to Section 9.3 below (and, in the case of termination
by Talecris, pursuant to Section 16.3 below).

 

9.3           Termination for Cause.

 

9.3.1        Change in Law.  This
Agreement may be terminated by either party upon notice, without penalty, if
there is any change in the law that makes operation of the Program as
contemplated in this Agreement illegal or commercially impractical.

 

9.3.2        Breach of BAA.  This
Agreement may be terminated by either party for a breach by the other party of
a material provision of the Business Associate Addendum attached hereto and
incorporated by reference as Exhibit E (the “BAA”) in accordance with the
terms of the BAA.

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

9.3.3        Material Breach.  This
Agreement may be terminated by either party for a breach of a material
provision of this Agreement by the other party that remains uncured thirty (30)
days following the breaching party’s receipt of written notice of such breach
from the non-breaching party.

 

9.3.4        Insolvency.  This
Agreement may be terminated by either party immediately upon notice if the
other party: (a) files a petition in bankruptcy under federal or state
bankruptcy laws which case or proceeding is not dismissed or vacated within
sixty (60) days, (b) becomes insolvent, (c) makes any assignment for
the benefit of creditors, or (d) has a receiver appointed for it.

 

9.4           Effect of Termination. 
Upon the termination or expiration of this Agreement:

 

9.4.1        Exit Assistance Services. 
CHR shall perform Exit Assistance Services in accordance with the Exit
Plan.

 

9.4.2        Consigned Inventory of Products. 
CHR shall return to Talecris all Talecris Consigned Inventory in the possession
of CHR in accordance with the Exit Plan. 
In the event of a termination by CHR for cause or a termination by
Talecris without cause, such return of Talecris Consigned Inventory will be at
the expense of Talecris.  In the event of
a termination by Talecris for cause, such return of Talecris Consigned
Inventory will be at the expense of CHR. 
Upon delivery and receipt of the Consigned Inventory and completion of
the Services, Talecris shall pay CHR, as expeditiously as is practicable, for
the Services performed to the reasonable satisfaction of and accepted by
Talecris, as of the date of termination, according to the applicable rates
under the terms of this Agreement.  All
moneys or accounts receivable arising from sales made by CHR prior to such expiration
or termination will be promptly paid over or assigned to Talecris.

 

9.4.3        Termination of Services.  Except as set
forth in the Exit Plan, CHR shall immediately cease work as provided in the
notice of termination, and shall cease to represent itself as providing
services to Talecris.

 

9.4.4        Product Supply.  If this
Agreement is terminated by Talecris for any reason other than pursuant to Section 92
or 9.3 or 16.3 as otherwise permitted under this Agreement, due to a breach by
CHR, then for the remaining period in the then current Term of this Agreement
as if it had not been terminated, Talecris will continue to supply the Product
to CHR for re-sale only to those patients who present with a prescription for
Product to CHR and will not charge CHR a per milligram price for the Product
that is higher than the price Talecris accepts for the Product from any other
commercial person in the United States within the same class of trade.

 

 

9.4.5        Restrictive Covenant.  In the event
that Talecris terminates this Agreement for cause, CHR and its Affiliates and
any successor entity or any entity in which certain designated employees
identified in Exhibit F (the “Designated Employees”) are employed
or have an ownership interest shall not administer any such program or engage
in the sale or provision of services or products competitive to Talecris’
business in the United States of America and its territories and military
installations for a period of one (1) year following the effective date of
termination.

 

9.4.6        Survival.  The
provisions of Sections 1, 3.2, 3.11, 3.12, 4.2, 9.4, 10, 11, 12, 14.2.3, 18,
20, 21, 22, 23, 24, 25, 27, 28, 29, 30, 31, 32 and 33 shall survive the
expiration or termination of this Agreement.

 

10.           CONFIDENTIALITY.

 

10.1         Definition of Confidential Information. 
As used in this Agreement, the term “Confidential Information” shall
mean any and all trade secrets and other confidential information disclosed by
a party (the “Disclosing Party”). 
“Confidential Information” shall include, without limitation, any
information concerning the Disclosing Party’s business plan, processes and
methods, product or process specifications and designs, inventions, technical
know-how, business and marketing plans, financial information, customer data,
research and development activities and other materials or information relating
to its business or activities which are not generally known to the public, all
confidential information of third-parties in the possession of the Disclosing
Party; and all notes, analysis, compilations, studies, summaries and other
material prepared by or for the Disclosing Party containing or based, in whole
or in part, on any information included in the foregoing.  The term “Confidential Information” shall not
include any information that is (i) publicly known or becomes publicly
known through no unauthorized act by the party receiving or accessing the
Confidential Information (the “Receiving Party”) or on the Receiving Party’s
behalf, (ii) rightfully received from a third party without an obligation
of confidentiality to the Disclosing Party with respect to the information
received, or (iii) approved by the Disclosing Party for disclosure.

 

10.2         Non-Disclosure. 
During the Term of this Agreement and thereafter, the Receiving Party
shall keep the Disclosing Party’s Confidential Information in the strictest
confidence (whether such Confidential Information was disclosed to the
Receiving Party before, on or after the Effective Date) and shall not disclose,
or permit the disclosure of, any Confidential Information to any third party
without the prior consent of the Disclosing Party.  The Receiving Party shall not use, or permit
the use of, any Confidential Information, without the prior consent of the
Disclosing Party, for any purpose other than in connection with the proper
performance of the Receiving Party’s obligations under this Agreement.  The Receiving Party shall use its best
efforts to prevent any inadvertent disclosure or unauthorized reproduction or
use of the Confidential Information.  The
Receiving Party will immediately advise the Disclosing Party in writing if the
Receiving Party becomes aware of any misappropriation or misuse by any person
of the 

 

 

Disclosing Party’s Confidential Information.  Notwithstanding the foregoing, the Receiving
Party may disclose the Confidential Information of the other party to the
extent such Confidential Information is required to be disclosed pursuant to a
requirement of a Regulatory Authority or law, provided that: (a) the
Receiving Party has given the Disclosing Party prior written notice of such
disclosure and takes all available steps to maintain the confidentiality of the
information disclosed; and (b) the Disclosing Party has been afforded a
reasonable opportunity to contest the necessity and scope of such
disclosure.  The Receiving Party
acknowledges and agrees that the Disclosing Party considers the Confidential
Information to be valuable, confidential and a trade secret.  The Receiving Party shall promptly return to
the Disclosing Party, in good order, the originals and all copies of
Confidential Information, regardless of the medium in which they are stored,
upon the termination or expiration of this Agreement or at any other time upon
the reasonable request of the Disclosing Party.

 

10.3         Confidential Information Relating to the
Program.  Without limiting the generality of the
foregoing, the following terms shall apply to Talecris’ Confidential
Information relating to the Program:

 

10.3.1     CHR shall limit the disclosure of Talecris’
Confidential Information relating to the Program to only members and managers
of CHR and employees and professional advisors of CHR; those of its personnel
with a need to know such information and who are subject to a written
confidentiality agreement at least as protective of Talecris’ Confidential
Information as the terms of this Section 10; and to professional advisers
of CHR.

 

10.3.2     CHR shall segregate and keep all Confidential
information relating to the Program separate from (i) other Confidential
Information of CHR, (ii) other Confidential Information of Talecris not
related to the Program, and (iii) the confidential information of third
parties.

 

10.3.3     Any information about the Program or the IG Program to
be disclosed by CHR to Talecris shall be disclosed only to a Program Manager
designated in writing by Talecris and not to any other Talecris employees.

 

11.           INTELLECTUAL PROPERTY.

 

11.1         Developments. 
Subject to Section 11.3 below, CHR shall own all inventions,
processes, know-how, enhancements, trade secrets and other intellectual
property developed by CHR and used by CHR in the course of providing the
Services to Talecris or in connection with any health management program
developed by CHR (collectively, “Developments”), provided that: (a) Talecris
shall own all Data (as defined in Section 11.2 below); and (b) CHR
shall grant to Talecris, and hereby grants to Talecris, a perpetual,
irrevocable, fully paid-up, royalty-free, non-exclusive, transferable, right
and license for Talecris, its agents, contractors and assigns to use, copy,
modify and create derivative works of the Developments 

 

 

in connection with the management of the Program and the provision of
the Services by Talecris or its contractors.

 

11.2         Data.  CHR
acknowledges and agrees that Talecris shall own and have access at all times to
all data relating to the Program, the IG Program and the provision of the
Services under this Agreement (collectively, the “Data”).  Notwithstanding the foregoing, any Data to be
accessed by Talecris shall first be de-identified by CHR in accordance with
applicable standards set forth in privacy rules promulgated pursuant to
the Administrative Simplification provisions of HIPAA.  CHR shall make available to Talecris, upon
the request of Talecris, aggregated de-identified patient information related
to Patients.

 

11.3         Pre-Existing Materials. 
Each Party shall retain ownership to all pre-existing and independently
developed intellectual property of such Party. 
Except as agreed otherwise in writing, to the extent that any
pre-existing or independently developed intellectual property is used by CHR in
the course of managing the Program or providing the Services, CHR shall grant,
and hereby grants, to Talecris a perpetual, irrevocable, fully paid-up,
royalty-free, non-exclusive, transferable right and license (or in the case of
third party materials, sublicense) for Talecris or its agents or assigns to
use, copy, modify and create derivative works of the Developments in connection
with the management of the Program and the provision of the Services by CHR or
its contractors.

 

11.4         HIPAA.  In addition
to the obligations set forth in Sections 11.1 through 11.3 above, the parties
shall execute the BAA concurrently with the execution of this Agreement.  Notwithstanding anything to the contrary in
this Agreement, all patient information covered by HIPAA shall be treated in
accordance with the terms of the BAA.

 

12.           AUDITS.  At Talecris’
expense, subject to applicable laws including those governing Patient
confidentiality, Talecris shall have the right during the Term and for three (3) years
after the expiration or termination of this Agreement to audit CHR’s financial
information pertinent to verification of CHR’s compliance with the financial
covenants and transactional details in connection with the Services provided in
this Agreement.  So long as CHR is in
compliance with financial and operational covenants, such audits shall be
limited to once per year.  In the event
of any breach by CHR of any covenant or other term of this Agreement, Talecris
shall have the right to audit CHR’s financial records and transactional details
relating to the Services at any time on thirty (30) days prior written notice.

 

13.           COMPLIANCE WITH LAW. 
Each of Talecris and CHR shall have obtained and maintain all applicable
material, professional and institutional licenses and certifications required
by federal and state laws and professional boards having jurisdiction over the
Services to be provided hereunder.  In providing
the Product and performing the Services, as applicable, each of Talecris and
CHR will comply with all applicable federal, state and local laws and
regulations, including without limitation, all applicable regulations and rules relating
to HIPAA, as well as drug manufacturing, pharmacy, health care provider and
insurance laws.  Further, CHR shall
comply with the terms of the BAA.  Each
of Talecris and CHR will make available to the other documentation of all licenses,
certificates, and subcontractor agreements prior to the execution of 

 

 

this Agreement and upon reasonable request
thereafter.  CHR shall ensure that all
regulatory filings and submissions made in connection with the Services are
made on a timely basis and are available for review by Talecris upon Talecris’
reasonable request.  Talecris shall
ensure that all regulatory filings and submissions made in connection with the
manufacture of the Product are made on a timely basis and are available for
review by CHR upon CHR’s reasonable request. 
CHR shall be solely responsible for, and Talecris shall have no
responsibility or liability for, ensuring that this Agreement and the
performance of the Services comply with HIPAA and with applicable reimbursement
and licensing laws, rules and regulations pertaining to specialty
pharmacies and pharmacy benefits managers. 
At any time upon fifteen (15) days notice to CHR, Talecris shall have
the right to inspect the premises where the Services are performed in order to
evaluate CHR’s compliance with its obligations under this Agreement, including
without limitation, its obligations with respect to quality, safety, security
and compliance with law.

 

14.           TRADEMARKS.

 

14.1         CHR Trademarks. 
Talecris shall, at its expense, market and promote the Prolastin Direct
Program.  In all such marketing and
promotional materials, Talecris shall disclose the extent to which Services are
provided by CHR.

 

14.2         Talecris Trademarks.

 

14.2.1     During the Term of this Agreement,
Talecris grants to CHR the non-exclusive, royalty-free right and license to use
the following trademarks: PROLASTIN DIRECT, PROLASTIN, GAMUNEX, GAMUNEX DIRECT,
TALECRIS BIOTHERAPEUTICS, TALECRIS CARES (collectively, the “Talecris
Trademarks”) in the United States of America solely for the purpose of
performing the Services and distributing the Products to Patients in accordance
with this Agreement.  CHR shall afford
Talecris reasonable opportunities during the Term hereof to inspect and monitor
the activities of CHR in order to ensure CHR’s use of the Talecris Trademarks
is in accordance with Talecris’ standards, specifications and
instructions.  CHR shall acquire no
right, title or interest in the Talecris Trademarks other than the limited
license stated herein.

 

14.2.2     CHR will not use, authorize or permit the
use of the Talecris Trademarks or the Talecris tradename as part of its firm,
corporate or business name or in any way, except to designate the Products
owned by Talecris under the terms of this Agreement.

 

14.2.3     CHR acknowledges and shall, at all times,
recognize, respect and protect Talecris’ sole ownership of any and all rights
in and to the Talecris Trademarks and shall not do anything, during or after
the Term of this Agreement, that could adversely affect such proprietary
rights.

 

14.2.4     Talecris reserves the right to withdraw
from this Agreement any Products that it believes may infringe any United
States of America or foreign patent or trademark.  In such event, Talecris shall immediately
notify CHR 

 

 

of the withdrawal
decision and such withdrawal shall immediately terminate CHR’s right to sell or
distribute the withdrawn Products under this Agreement.

 

14.3         No Other License. 
Except as specifically set forth in this Section 15, nothing in
this Agreement shall be deemed a license by either party to use the trademarks,
trade names or service marks of the other party.

 

15.           PUBLICITY.  Neither Party shall directly or indirectly
publish, approve or issue any press release or public statement relating to the
relationship of the Parties to this Agreement or any Products furnished or Services
performed by CHR for Talecris (each, a “Press Release”), without the prior
written consent of the other Party’s authorized representative as to both
content and timing of such Press Release, which approval may not be
unreasonably withheld, delayed or conditioned by the non-publishing Party.

 

16.           BUSINESS CONTINUITY.

 

16.1         Business Continuity Plan. 
CHR shall provide and, at all times during the Term, shall maintain the
capability (i) to continue operations due to a loss, interruption or
unexpected cause of removal of CHR’s facility/site; and (ii) to recover
from unpredicted interruptions within its operating environment or technology
infrastructure, resulting from a loss or disruption ranging from a temporary
loss of a critical system component to a full CHR facility/site disaster.  Without limiting the generality of the
foregoing, CHR shall comply with the terms of the Business Continuity Plan
attached hereto and incorporated herein by reference as Exhibit G,
as the same may be amended as agreed by the Parties in writing, in responding
to any circumstances that threatens to impair or prevent the continued
operation of the Services or CHR’s business. 
On each anniversary of the Effective Date of this Agreement, CHR shall
deliver to Talecris an updated Business Continuity Plan.  Each Business Continuity Plan delivered by
CHR shall be subject to Talecris’ review, modification, acceptance and
approval.  Any modifications or updates
thereto as reasonably requested by Talecris as such modifications or updates
are developed by CHR shall be attached thereto and incorporated therein and
herein, in their entirety, by this reference. 
As part of each Business Continuity Plan, CHR shall provide contingency
plans to recover from site disasters, fires, floods, explosions, and other
events likely to result in business interruption.  Talecris’ review and approval of CHR’s
Business Continuity Plans shall not act as a waiver of, nor in any way effect,
CHR’s obligations hereunder.

 

16.2         Testing.  CHR, at its
sole expense, shall maintain access to an effective disaster recovery site and
shall execute planned annual tests of the Business Continuity Plan, at a time
which is mutually acceptable to Talecris and CHR.  Within ten (10) days of the completion
of such testing, CHR shall provide a written detailed summary of the test and
test results to Talecris, Talecris shall also be entitled, at its option and
sole expense, to conduct additional reasonable periodic testing of CHR’s
Business Continuity Plan, on reasonable notice, and require CHR to participate
in such testing and in the demonstration and documentation of its 

 

 

continued efficacy, to the extent such testing pertains to the Services
provided by CHR hereunder.

 

16.3         Right to Terminate. 
The parties agree that, following an interruption of CHR’s business or
disaster that calls for implementation of the Business Continuity Plan, if the
Services are not reinstated within the time periods set forth in the Business
Continuity Plan, Talecris shall have the right to immediately terminate this
Agreement upon written notice to CHR.  In
the event of such termination, Talecris will pay for Services performed and
accepted prior to the effective date of such termination.  CHR waives and forfeits all other claims for
payment and damages including, without limitation, anticipated profits or
revenue or other economic loss, arising out of or resulting from such
termination.

 

17.           REPRESENTATIONS AND WARRANTIES

 

17.1         Authority; No Violation; Binding
Obligation.  Each Party represents and warrants to the
other, as of the Effective Date, that (i) such Party has the full right,
power and authority to enter into this Agreement; (ii) the execution,
delivery and performance by such Party of this Agreement are within its powers
and have been duly authorized by all necessary action; (iii) the execution
of this Agreement by such Party and the performance by such Party of its
obligations and duties hereunder do not and will not violate any agreement,
applicable law, judgment, injunction, order or decree to which it is a party or
by which it is otherwise bound; and (iv) when executed and delivered by
it, this Agreement shall constitute the legal, valid and binding obligation of
such Party, enforceable against such Party in accordance with its terms.

 

17.2         Permitted Employees and Permitted
Contractors Only.  CHR represents and warrants that all Services
performed by CHR pursuant to this Agreement will be performed only by either (i) full-time
employees of CHR that are acting within the scope of their employment and have
executed written agreements with CHR containing provisions legally equivalent
to those of Section 11 of this Agreement (the “Permitted Employees”) or (ii) individual
contractors of CHR that have executed written agreements with CHR containing
provisions legally equivalent to those of Sections 10, 18.2, 18.3 and 18.4 of
this Agreement (the “Permitted Contractors”). 
CHR shall be responsible for the acts and omissions of all of its
Permitted Employees and Permitted Contractors under this Agreement.

 

17.3         Debarment.  Each of
Talecris and CHR represents and warrants that it is not currently debarred,
suspended or otherwise excluded by any government agency from receiving federal
contracts.  CHR further certifies by
accepting this Agreement or any part thereof that no CHR personnel or
subcontractor assigned to perform services under this Agreement is debarred,
suspended or proposed for debarment by the United States Government.  Debarment, suspension or proposed debarment
of a Party by the United States Government will constitute grounds for
automatic termination of this Agreement by the other Party.

 

 

17.4         Compliance with Law. 
Each of Talecris and CHR represents and warrants that it holds and shall
maintain, throughout the Term of this Agreement, all applicable material,
professional and institutional licenses and certifications required by federal
and state laws and professional boards and entities having jurisdiction over
the Products and Services to be provided hereunder.  CHR further warrants that its performance of
the Services will comply with all applicable federal, state and local laws and
regulations, including without limitation, all applicable regulations and rules relating
to HIPAA, as well as pharmacy, health care provider and insurance laws.  Talecris further warrants that its provision
of Product will comply with all applicable federal, state and local laws and
regulations, including, without limitation, all applicable regulations and rules relating
to health care provider and insurance laws.

 

17.5         CHR Employee and Subcontractor
Qualifications.  CHR represents and warrants that CHR’s
employees and subcontractors performing Services hereunder shall have and
continue to maintain, throughout the Term of this Agreement, all applicable
material professional and institutional licenses and certifications required by
applicable federal and state laws and professional boards and entities having
jurisdiction over the provision of Services.

 

17.6         HIPAA.  Without
limiting the generality of the representation and warranty set forth in Section 17.4
above, CHR acknowledges and agrees that it is a “covered entity” for the
purposes of HIPAA, as such term is defined in 45 C.F.R. § 160.103.  CHR represents and warrants that as of the
Effective Date, it is in full compliance with its obligations as a covered
entity pursuant to the HIPAA laws, regulations and rules.  CHR further represents and warrants that it
will comply with all applicable HIPAA laws, regulations and rules throughout
the Term.

 

17.7         Performance. 
CHR represents and warrants that the Services will be performed in a
good and workmanlike mailer.  CHR further
represents and warrants that the Services will be performed in accordance with
normally accepted industry standards.

 

17.8         Key Performance Indicators. 
CHR will use commercially reasonable efforts to perform the Services in
accordance with KPIs.

 

17.9         Confidentiality Practices. 
Each of Talecris and CHR represents and warrants that it has
implemented, and will use in the provision of the Product or Services, business
practices, technology, operating procedures and methodologies consistent with
industry best practices to prevent the disclosure or distribution of the
other’s Confidential Information in any form or manner not specifically authorized
or requested by the other, including without limitation distributing any of the
other’s Confidential Information in a form or manner that is not approved by
the other in advance, and sending any of the other’s Confidential Information
to third parties.

 

17.10       Products. 
The Products are warranted by Talecris only as set forth on the
applicable Product label or insert.  CHR
shall not make or provide any additional 

 

 

warranties with respect to the Product, and CHR shall defend, indemnify
and hold harmless Talecris, its officers, directors, employees, shareholders
and agents from and against any Claim (as defined in Section 18 below)
based on any such additional warranty.

 

17.11       EXCEPT
AS SPECIFICALLY SET FORTH IN THIS SECTION 17, ALL OTHER WARRANTIES,
EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTY OF
NON-INFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE
ARE HEREBY DISCLAIMED AND EXCLUDED.

 

18.           INDEMNIFICATION

 

18.1         Talecris, at its own expense, shall
defend, indemnify and hold CHR, its shareholders, officers, directors,
employees, agents, successors and permitted assigns (the “CHR Indemnitees”)
harmless from and against all claims, losses, liabilities, costs, charges,
expenses (including reasonable attorneys’ fees) or damages (collectively,
“Claims”) by third parties for personal injuries or death that result from, or
arise out of, (a) any design, manufacturing or labeling defect in any
Product, (b) any failure by Talecris to supply Product pursuant to this
Agreement or (c) any negligent or wrongful act or omission in the
performance of this Agreement by any of Talecris or its employees, contractors
or agents.

 

18.2         CHR shall defend, indemnify and hold
Talecris, officers, shareholders, directors, employees, agents, successors and
assigns (the “Talecris Indemnitees”) harmless from and against all Claims, in
respect of injury (including death) to any persons or loss or damage to any real
or tangible property which may arise out of any act or omission of CHR, its
contractors, employees or agents in the performance of the Services under this
Agreement, provided that, CHR shall not be liable for nor be required to
indemnify Talecris in regard to any injury, loss or damage to the extent that
such injury, loss or damage is caused by any negligent or wrongful act or
omission on the part of Talecris or its employees, contractors or agents.

 

18.3         CHR shall defend, indemnify and hold the
Talecris Indemnitees harmless from and against all Claims arising from any acts
of fraud, embezzlement or dishonesty committed by CHR, its contractors,
employees or agents, acting alone or in collusion with another party, in the
performance of the Services hereunder. 
The absence of insurance shall not diminish CHR’s responsibility to
indemnify Talecris.

 

18.4         Each of Talecris and CHR shall defend,
indemnify and hold the Talecris Indemnitees, in the case of CHR, and the CHR
Indemnitees in the case of Talecris, harmless from and against all Claims by
third parties arising from the indemnifying Party’s or its employees’,
subcontractors’ or agents’ (i) breach of any representation, warranty or
covenant hereunder, or failure to perform its obligations under this Agreement;
(ii) violation of any federal, state or local law, regulation, statute or
ordinance, including, without limitation, applicable privacy and security laws,
rules, regulations and other binding guidance (including, 

 

 

without limitation, HIPAA, state and local pharmacy, health care
provider and insurance laws and regulations); and/or (iii) failure to
comply with the confidentiality obligations set forth in Section 11.

 

19.           INSURANCE.

 

19.1         Without limiting its responsibilities
under Section 18, CHR shall maintain in force at all times during the term
of this Agreement, with insurance companies acceptable to Talecris, the
following insurance including any special terms indicated:

 

19.1.1     CHR staff are employees of ADP, which maintains
employer’s Liability Insurance and Workers’ Compensation Insurance, including
coverage for occupational injury, illness and disease, and other similar social
insurance in accordance with the laws of the country, state or territory
exercising jurisdiction over the employee with minimum limits per employee and
per event of $1,000,000 and a minimum aggregate limit of $1,000,000 or the
minimum limits required by law, whichever limits are greater.  CHR will maintain equivalent or greater coverage
in the event CHR staff are converted to being employees.

 

19.1.2     Commercial General Liability Insurance in respect of
CHR’s liability for loss of or damage to property and against liability in
respect of injury, including death, resulting therefrom, for the sum of not
less than $1,000,000 for any one occurrence and $2,000,000 in the aggregate
annually.  Such policy shall include
products/completed operations and broad form contractual coverage.  This coverage shall be endorsed to name
Talecris as additional insured.

 

19.1.3     Property Insurance, including Extra Expense and
Business Income coverage, for all risks of physical loss of or damage to
buildings, business personal property or other property that is in the
possession, care, custody or control of CHR pursuant to this Agreement.  Such insurance shall have a minimum limit
adequate to cover loss of maximum CHR inventory of Talecris· product valued at the current wholesale
price.  This coverage shall be endorsed
to name Talecris as loss payee in respect to property of others.

 

19.1.4     Automotive Liability Insurance covering use of all
owned, non-owned and hired automobiles for bodily injury, property damage with
a minimum combined single limit per accident of $1,000,000, uninsured motorist
and underinsured motorist liability with the minimum limit required by
law.  Combined Single Limit for bodily
injury and property damage for the sum of not less than $1,000,000 per
accident.

 

19.1.5     Commercial Crime Insurance, including blanket coverage
for Employee Dishonesty and Computer Fraud, for loss or damage arising out of
or in connection with any fraudulent or dishonest acts committed by the 

 

 

employees of CHR, acting
alone or in collusion with others, including the property and funds of others
in their possession, care, custody or control, with a minimum limit per event
of $3,000,000.

 

19.1.6     Professional Liability and Errors and Omissions
Liability Insurance covering liability for loss or damage due to an act, error,
omission or negligence with a minimum limit per event of $10,000,000.

 

19.1.7     Umbrella Liability Insurance with a minimum limit of
$10,000,000 in excess of the insurance coverage described above.

 

19.1.8     Transit/cargo insurance covering Talecris consigned
product against damage due to mishandling and lost or delayed shipments.  Such insurance shall have a minimum limit of
$100,000 per conveyance.  This coverage
shall be endorsed to name Talecris as loss payee in respect to property of
others.

 

19.1.9     CHR shall have its insurance carrier or carriers
furnish to Talecris certificates that all insurance required under this
Agreement is in force, such certificates to indicate any deductible and/o  self insured retention and stipulate that the
insurer will provide Talecris with no less than thirty (30) days prior written
notice of cancellation, termination, non-renewal or material change.

 

20.           LIMITATION OF LIABILITY.  IN NO EVENT SHALL EITHER PARTY, ITS
AFFILIATES AND THEIR RESPECTIVE SHAREHOLDERS, MANAGERS, DIRECTORS, OFFICERS,
EMPLOYEES AND AGENTS BE LIABLE FOR ANY INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE
OR CONSEQUENTIAL DAMAGES, INCLUDING, WITHOUT LIMITATION, LOST PROFITS, HOWEVER CAUSED
OR ARISING, WHETHER OR NOT SUCH PARTY HAS BEEN INFORMED OF THE POSSIBILITY OF
THEIR OCCURRENCE.

 

21.           DISPUTE RESOLUTION.  If the parties fail to resolve any claim,
dispute, or controversy of whatever nature arising out of or relating to this
Agreement (other than one relating to a breach of Section 10 or one
relating to the validity, enforceability, infringement or misappropriation of
the Talecris Trademarks, or other intellectual property rights of the parties,
which shall not be subject to this Section 21), or concerning the
interpretation, effect, termination, validity, performance and/or breach of
this Agreement (a “Claim”), either party may refer the Claim, by notice to the
other party, to their respective officers designated below or such other officers
as the parties may designate in writing from time to time, for attempted
resolution by good faith negotiations within thirty (30) days after that notice
is received.

 

The designated officers are
as follows:

 

	
  For
  Talecris:

  	
  Senior
  Director

  
	
   

  	
   

  
	
  For
  CHR:

  	
  President and Chief
  Executive Officer

  

 

 

Pending resolution of any
such dispute, CHR shall continue to perform its obligations under this
Agreement, and Talecris shall continue to make payment to CHR for any
undisputed items.  If such dispute is not
resolved by negotiation by the end of the thirty (30) day period, then the
Claim shall be submitted to nonbinding mediation administrated by the American
Arbitration Association under its Commercial Mediation Rules.  If the parties are unable to resolve the Claim
through mediation, then the parties shall be free to pursue any legal or
equitable remedy available to them.  Each
Party will bear its own attorneys’ fees and other costs and expenses.

 

22.           NOTICE. 
All notices and other communications that may be or are required to be
given hereunder shall be in writing and shall be deemed to have been duly given
on the date of delivery if personally delivered; five days after mailing if
mailed, first class postage prepaid; or one day after mailing if sent by independent
overnight courier, and shall be addressed as follows:

 

If
to CHR:

Centric
Health Resources

17877
Chesterfield Airport Rd.

Chesterfield,
Missouri 63005

Attn:
Craig L. Kephart, President and CEO

 

If
to TALECRIS:

Talecris
Biotherapeutics, Inc.

4101
Research Commons

79
Alexander Drive

Research
Triangle Park, NC 27709

Attn: Senior Vice President
and General Manager, Portfolio Management and US Business

 

With
a copy (which shall not constitute notice) to:

 

Talecris
Biotherapeutics, Inc.

4101
Research Commons

79
T.W. Alexander Drive

Research
Triangle Park, NC 27709 Attn: General Counsel

 

Either party may change its
address for purposes of notice pursuant to this Agreement by notifying the
other party of such change of address in the manner set forth above, except
that notices for changes of address are effective only upon receipt by the
other Party.

 

23.           ENTIRE AGREEMENT.  This Agreement, together with the Exhibits
attached hereto, contains the entire understanding between the parties and
supersedes and cancels any and all prior agreements, written or oral, between
them regarding the within subject matter (including the Term Sheet and the
Original Agreement), except with respect to Services furnished by CHR prior to
such Effective Date, which will be accounted for and settled in accordance with
the provisions of the Original Agreement. 
There are no representations, agreements, arrangements or
understandings, oral or written, between or among the parties hereto relating
to the subject matter of this Agreement that are not fully expressed herein.

 

 

24.           AMENDMENT.  This Agreement may not be amended except in a
writing signed by the authorized representatives of both of the parties hereto.

 

25.           ASSIGNMENT.  This Agreement may not be assigned or
transferred by CHR without the prior written consent of Talecris.  Any attempted assignment in violation of this
Section 25 shall be null and void. 
A Change of Control of CHR shall be deemed an assignment of this
Agreement.  For the purposes of this
Agreement, a “Change of Control” shall mean an equity sale, reorganization,
merger, consolidation or other form of corporate transaction or series of
transactions, in each case, with respect to which persons who were the holders
of equity interests in CHR immediately prior to such equity sale,
reorganization, merger, consolidation or other transaction do not, immediately
thereafter, own more than fifty percent (50%) of the combined voting power
entitled to vote generally in the election of managers or directors of the
sold, reorganized, merged or consolidated company’s then outstanding voting
securities, in substantially the same proportions as their ownership
immediately prior to such equity sale, reorganization, merger, consolidation or
other transaction.  Talecris may assign
this Agreement upon thirty (30) days notice to CHR.

 

26.           RELATED PARTY TRANSACTIONS.  Throughout the term of this Agreement, CHR
will disclose in writing to Talecris any contemplated related party
transactions at least thirty (30) days in advance of such transaction.

 

27.           GOVERNMENT AUDITS.  Until the expiration of four (4) years
following the furnishing of services under this Agreement and any related
agreement between the parties, CHR shall maintain this Agreement and such
related agreements and its books, documents and records of any kind that are
necessary to certify the nature and extent of the costs incurred by CHR
pursuant to this Agreement, and CHR shall make these items available to the
Secretary of Health and Human Services, the Comptroller General of the United
States, or the duly authorized representatives of either of them upon their
written request.  If CHR performs any of
the duties assumed pursuant to this Agreement or any related agreement through
subcontract with a third party (without regard to whether the party is an
affiliate of CHR) and such subcontract shall have a value of at least ten
thousand dollars ($10,000) over any twelve (12) month period, then such
subcontract shall require subcontractors to comply with the requirements
contained in this Section 28.

 

28.           BINDING EFFECT.  Subject to the foregoing, this Agreement
shall be binding upon and shall inure to the benefit of the parties hereto and
their respective successors and permitted assigns.

 

29.           SEVERABILITY.  Each Article and Section hereof
shall be considered severable, and if for any reason any Article or Section is
determined to be invalid under current or future law, such invalidity shall not
impair the operation of or otherwise affect the valid portions of this
Agreement.

 

30.           WAIVER. 
The terms, covenants and conditions of this Agreement may be waived only
by a written instrument executed by the party waiving compliance.  The failure of any party at any time or times
to require performance of any provision of this Agreement shall in no manner
affect the right at a later date to enforce the same or to enforce any future
compliance with or performance of any of the provisions hereof.  No waiver by any party of any condition or
other 

 

 

breach of any provision, term or covenant in this
Agreement whether by conduct or otherwise, in any one or more instances, shall
be deemed to be or construed as a further or continuing waiver of any such
condition or the breach of any other provision, term or covenant of this
Agreement.

 

31.           TITLES. 
The titles of the Sections herein have been inserted as a matter of
convenience for reference only, form no part of this Agreement, and shall not
control or affect the meaning or construction of any of the terms or provisions
hereof.

 

32.           NO THIRD-PARTY BENEFICIARIES.  This Agreement is intended for the benefit of
the parties hereto and their respective successors and permitted assigns and is
not for the benefit of, nor may any provision hereof be enforced by, any other
person.

 

33.           GOVERNING LAW; VENUE.  This Agreement and all rights and obligations
hereunder shall be governed by the internal laws of the State of North
Carolina, without regard to principles of conflicts of laws.  Any legal action arising out of this Agreement
shall be brought in a court having jurisdiction in Wake County, North
Carolina.  Each party hereby irrevocably
submits to the exclusive jurisdiction of the state and federal courts sitting
in the State of North Carolina, Wake County for the adjudication of any dispute
brought hereunder, in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of this
Agreement), and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or proceeding is
improper.  Each party hereby irrevocably
waives personal service of process and consents to process being served in any
such suit, action or proceeding by mailing a copy thereof via registered or
certified mail or overnight delivery (with evidence of delivery) to such party
at the address in effect for notices to it under this Agreement and agrees that
such service shall constitute good and sufficient service of process and notice
thereof.  Nothing contained herein shall
be deemed to limit in any way any right to serve process in any manner
permitted by law.

 

34.           COUNTERPARTS.  This Agreement may be executed in one or more
counterparts and each of such counterparts shall, for all purposes, be deemed
to be an original, but all of such counterparts shall constitute one and the
same instrument.

 

 

IN WITNESS WHEREOF, CHR and
Talecris have caused this Agreement to be executed by their officers who have
authority to bind their respective companies.

 

	
   

  	
  CENTRIC
  HEALTH RESOURCES, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:
  

  	
  /s/
  Craig L. Kephart

  
	
   

  	
  Name:

  	
  Craig
  L. Kephart, President and CEO

  
	
   

  	
   

  
	
   

  	
  TALECRIS
  BIOTHERAPEUTICS, INC.

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  John R. Perkins

  
	
   

  	
  Name:

  	
  John
  R. Perkins

  
	
   

  	
  Title:

  	
  SVP &
  General Manager

  
	
   

  	
   

  	
  Portfolio
  Management and US Business

  
	
   

  	
  Date:

  	
   

  
	
   

  	
   

  
	
   

  	
   

  
	
   

  	
  By:

  	
  /s/
  Charles Gayer

  
	
   

  	
  Name:

  	
  Charles
  Gayer

  
	
   

  	
  Title:

  	
  Senior
  Director, Pulmonary

  
	
   

  	
  Date:

  	
  January 12, 2009

  

 

Attachments:

 

Exhibit A — Detailed
Description of Services and Project Management

Exhibit B — Pricing
Schedule

Exhibit C — Additional
Compensation - Prolastin Direct Program

Exhibit D — [***] Pilot
Program

Exhibit E — Business
Associate Addendum

Exhibit F — Designated
Employees

Exhibit G -   Business
Continuity Plan

 

***         CONFIDENTIAL TREATMENT REQUESTED

 

 

EXHIBIT A

 

DETAILED DESCRIPTION OF
SERVICES AND PROJECT MANAGEMENT

 

1.             Project
Managers

 

	
  CHR Project Manager:

  	
  Michelle Hefley

  
	
   

  	
  Chief Operating Officer

  
	
   

  	
  Centric Health Resources

  
	
   

  	
  17877 Chesterfield Airport
  Rd.

  
	
   

  	
  Chesterfield, Missouri
  63005

  
	
   

  	
  Phone: (636) 519-2400

  
	
   

  	
  Fax: (866) 862-8818

  

 

	
  Talecris Project
  Manager:

  	
  Charles Gayer

  
	
   

  	
  Senior Director, Pulmonary
  Talecris Biotherapeutics, Inc.

  
	
   

  	
  101 Research Commons 79
  T.W. Alexander Drive

  
	
   

  	
  Research Triangle Park, NC
  27709

  
	
   

  	
  Phone: (919) 316-6205 Fax:
  (919) 316-6488

  

 

2.             Prolastin
Direct Program

 

a.             Upon receipt of instructions
from the Patient and a valid physician’s prescription for Services, CHR shall
furnish or arrange for the provision of such services as follows:

 

(i)            Intake Form.  CHR will provide or arrange to provide intake
services on behalf of the Program, which intake services shall include the
completion of an Intake Form for the applicable Patient by means of
telephone, United States mail service, or facsimile communication, verification
of insurance coverage and prior authorization, as necessary.  “Intake Form” means the form to be used by
CHR to gather information regarding, among other things, Patient demographics,
referral information, primary and secondary insurance, and physician and
medical information.

 

(ii)           Authorization.  CHR shall seek prior authorization from the
Patient’s Payor.  Upon receipt thereof,
CHR shall commence to furnish or arrange for the furnishing of Services to such
Patient in a timely manner, as more specifically described in Paragraph 3
below.

 

(iii)          Reimbursement.  For all Products and/or Services furnished to
Patients, CHR will submit a claim to the Patient and/or applicable Payor for
Services and/or will bill the patient and/or applicable Payor for such Products
and/or Services.  CHR will manage the
collections associated with said current and past due claims and assume
responsibility for administration of all collection efforts; provided, however,
that Talecris shall remain financially responsible for any bad debt resulting
from nonpayment for any Services actually furnished to a Patient.

 

(iv)          Complete Information.  Notwithstanding anything contained hereon or
elsewhere to the contrary, CHR shall be under no obligation to provide any Services
hereunder to 

 

 

Patients until it has all
the information necessary to complete the Intake Form in a manner
satisfactory to CHS, and has received proper prior authorization from the Payor
and/or Patient, as applicable, to deliver Services to the applicable Patient.

 

(v)           CHR shall gather all
prescription and patient information required to dispense the prescriptions to
Patients as permitted by law, in order to complete all pertinent insurance
forms and documents necessary in order to obtain reimbursement from any
applicable Payor for Services provided under this Agreement.

 

3.             Services

 

General Services

 

·              Initial and on-going
Talecris program staff training at appropriate levels

 

·              Initial training, carried
out jointly by CHR, Talecris and AlphaNet

 

·              On-going training utilizing
Talecris-approved materials

 

·              Management of program per
Talecris specific business rules

 

·              Transfer and maintenance of
a 1-800 call center for the program

 

·              Transfer and maintain a
1-800 fax center for the program

 

·              Hours of normal business
operation 7:00 AM-6:00 P.M. CST Monday-Friday

 

·              24/7 on-call clinical
support (Pharmacy and Nursing)

 

·              Establish and maintain a
Website to support access to Talecris key program metrics reporting (Dashboard
concept)

 

·              Maintain all required
state/federal pharmacy and wholesale licenses to include proper certification
of Pharmacy Technicians per Missouri law

 

·              Secure and maintain state
Medicaid provider status

 

·              Maintain Medicare provider
status

 

·              Maintain and manage a
secondary pharmacy network as required by Medicaid for Product distribution
(Medicaid in-state providers)

 

·              Warehousing, distribution
and dispensing of Product

 

·              Warehousing and distribution
for associated infusion supplies

 

·              Warehousing, distribution
and retrieval of medical waste containers

 

·              Inventory and storage of
Product in compliance with Talecris’/PI requirements

 

·              Performing a physical
inventory of Product and reporting detailed inventory at mutually agreed upon
intervals

 

·              Quarantine of Product in
compliance with Talecris’ requirements

 

·              Maintaining mutually
agreed-upon Talecris Consigned Inventory levels

 

 

·              Maintain a validated
operations system for the purposes of order processing, dispensing, billing of
third parties and management of Talecris accounts receivable

 

·              Management of a patient and
physician database

 

·              Distribution of Talecris
written communications and patient/physician educational materials

 

·              Return goods processing and
coordination as required by Talecris

 

Order Fulfillment Services

 

·              Receiving orders

 

·              Obtaining valid
prescriptions as required

 

·              Managing and dispensing of
Products to Patients

 

·              Coordination of patient
supply orders with Alpha Net

 

·              Managing and dispensing of
infusion supplies

 

·              Picking, packing, and
labeling of Products as required

 

·              Dispensing of Products in
accordance with applicable state and federal regulations

 

·              Coordination of shipments
with customers

 

·              Maintenance and tracking of
shipments in an appropriate database

 

·              Shipping of Products and
supplies to patients, physicians or hospitals or other licensed facility - HHC,
Pharmacy, etc.

 

·              Tracking of distributed
Products, by appropriate lot number

 

·              Full Class I Recall
capabilities for Products dispensed by CHR

 

·              Verifying receipt by the
patient, physician or hospital of Products

 

·              Distribution of Product
information as required by Talecris

 

·              Order fulfillment related to
“Easy Access” program or other patient assistance program as implemented by
Talecris

 

Reimbursement Services

 

·              Management of Talecris Payor
contracts and Carrier Contracts

 

·              Assist in establishing new
Talecris Payor contracts and Carrier Contracts

 

·              Administration of “single
patient contracts”

 

·              Application and management
of the “sole source” exception requests for necessary Medicaid provider waivers

 

·              Utilization of CHR Medicaid
provider numbers and PBM provider status for the submission and collection of
claims

 

·              New patient intake (data
collection)

 

·              Verification of coverage and
benefits

 

 

·                                          Prior
authorization if required

 

·                                          Obtain
necessary consents

 

·                                          Inform Patient
of coverage and co-pay responsibilities

 

·                                          Patient
coverage denials

 

·                                          Contact
appropriate parties

 

·                                          Appeal the
case, according to mutually agreed-upon policies

 

·                                          Communicate
with patient and physician regarding coverage and status

 

·                                          Assembling of
appropriate documentation for re-submission to Payors

 

·                                          Billing of
third party payers on behalf of Talecris

 

·                                          Claims
adjudication

 

·                                          Management of
collections

 

·                                          Collection of co-pays
and deductible amounts

 

·                                          Referral and
coordination of Patients to assistance program pursuant to Talecris Policies

 

·                                          Cash
Application

 

·                                          Ability to
process credit card payments

 

·                                          Submissions of
payments to a Talecris lock box

 

Clinical
Support/Training Coordination Services

 

·                                          24/7 on-call
clinical support (Pharmacy/Nursing)

 

·                                          Coordination of
nursing required for Product administration

 

·                                          Aid in
answering Product questions as approved by Talecris

 

·                                          Triage
medical/clinical questions to Talecris Clinical Communications Aid in providing
Product administration information as approved by Talecris

 

·                                          Follow-up calls
to support customer surveys as approved by Talecris

 

·                                          Triage Product
issue calls to Talecris per current Talecris Policies

 

·                                          Distribution of
Product information and educational materials, as appropriate

 

Reporting

 

·                                          Reporting as
agreed upon regarding customer demographics, shipping information, quantity,
lot numbers and billing information

 

·                                          Sales
transactions

 

·                                          Shipments

 

·                                          Billing and
collections

 

·                                          Cash
applications

 

 

·                                          New accounts

 

·                                          Returns and
credits

 

·                                          Temperature
monitoring

 

·                                          Inventory
receipt and on hand

 

·                                          Adverse event
reporting as required by Talecris - mechanism to Talecris CC/Drug safety

 

·                                          Agreed-upon
performance measures

 

·                                          Other reports
as mutually agreed upon

 

·                                          # of Patients
enrolled

 

·                                          Trends

 

·                                          Average time on
Services

 

·                                          Physicians

 

·                                          Demographics

 

·                                          # of Patients

 

·                                          Customer
Service/Reimbursement/Pharmacy Calls

 

4.                                      Nursing
Services

 

CHR
will locate, contract with and coordinate necessary nursing services for the
administration of Talecris Products related to this program.  Costs associated with coordination of the
nursing function are included in the base fee. 
Any fees incurred for nursing services (other than coordination) shall
be as set forth on the Pricing Schedule (Exhibit B).

 

5.                                      Supplies
and Equipment

 

CHR
shall provide all necessary supplies and equipment associated with the
administration of Products dispensed under this program.  CHR shall ship such supplies to each Patient
along with each such Patient’s regular Product shipment.  The cost of such supplies/equipment shall be
paid as set forth on the Pricing Schedule. 
CHR and AlphaNet shall jointly determine the nature of such supplies and
equipment based on Patient preferences. 
The Pricing Schedule (Exhibit B) defines pricing and billing
for supplies.

 

6.                                      Shipping

 

CHR
will provide Talecris-approved shipping containers and materials (e.g.,
packing, cooling blocks, labels) for the shipment of Products.  No other materials may be used or accompany
the Product.  The cost of such materials
shall be paid as set forth on the Pricing Schedule.  Talecris reserves the right to select
specific packaging materials and, in such event, Talecris shall be entitled to any
savings and shall bear any additional expense. 
Unless otherwise stated herein, a mutually agreeable carrier shall ship
Products covered under this Agreement on an “overnight” basis directly to
Patients or other designated Talecris customers.

 

 

EXHIBIT
B

 

PRICING
SCHEDULE

 

(1)                                  Standard Fees.  The standard fees for the Services provided
by CHR with respect to the Program include the Base Fee (defined below),
certain pass-through costs and adjustments for Alpha Advocates as described
below in this Section.

 

(a)                                  Base Fee.  The “Base Fee” consists of the Prolastin Base
Fee (as defined below) and the Gamunex Base Fee (defined below).

 

(i)            The initial
base fee (“Prolastin Base Fee”) for the Services provided by CHR under this
Agreement is $[***] per milligram of Product dispensed to Patients in the first
calendar year in the Term of this Agreement, subject to adjustment as provided
below.  The Prolastin Base Fee will be
automatically adjusted by CHR, effective as of January 1 of each calendar
year, commencing with January 1, 2009, by the annual average percentage
increase in the Consumer Price Index (“CPI-U”), U.S. City Average, All Items,
published monthly by the Bureau of Labor Statistics of the U.S. Department of
Labor (or if the Index is no longer published or issued, any successor index or
other reliable governmental or nonpartisan publication evaluating the
information previously used in the determining the Index that is mutually
selected by the parties) for the most recently completed 12 month period for
which the CPI-U percentage is available at the time the adjustment calculation
is performed by CHR (“CPI-U Adjustment”)

 

(ii)           The initial
base fee (“Gamunex Base Fee”) for the Services provided by CHR under this
Agreement in connection with the IG Program is $[***] per gram of Gamunex
Product dispensed to Patients in the first calendar year in the Term of this
Agreement, subject to adjustment as provided below.  The Gamunex Base Fee will be automatically
adjusted by CHR, effective as of January 1 of each calendar year,
commencing with January 1, 2009, by the CPI-U Adjustment formula set forth
above.

 

(b)                                 Pass-Through
Costs.  In addition to the Base Fee,
Talecris will reimburse CHR for certain reasonable costs on a pass-through
basis.  The costs that will be reimbursed
on pass-through basis are as follows:

 

(i)            all nursing
infusion services.

 

(ii)           all infusion
and other supplies related to Product preparation and infusion.

 

(iii)          all shipping
materials and supplies for Product, including, without limitation, boxes, tape,
insulation and freezer bricks.

 

(iv)          all fuel
surcharges assessed by CHR’s shipping company(ies);

 

(v)           all other items
or costs mutually agreed upon by the parties.

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

CHR will be responsible for
negotiating price, ordering necessary supplies directly from supply
manufacturers, and paying manufacturers unless otherwise specified by
Talecris.  CHR shall ensure that Talecris
is made an intended third-party beneficiary of all contracts, bids or
quotations that relate to pass-through costs such that Talecris shall have the
right to enforce such contracts, bids or quotations on its own behalf.  Talecris, at its discretion, may negotiate
terms directly with supply manufacturers, and terms negotiated by Talecris
shall control as soon as CHR’s contract with such manufacturer, if any, is
terminated.  CHR will bill Talecris for
pass-through costs on a monthly basis based on actual usage.  Talecris will make payment to CHR within 45
days of receipt of the invoice by Talecris.

 

(c)                                  Alpha Advocates.  As part of the Base Fee, the Services
provided by CHR include the services of [***] Alpha Advocates.  [***] If an Alpha Advocate position remains
unfilled for a period of 45 days or longer, CHR will reduce its monthly invoice
for the Base Fee by [***] of the then effective contract value for an Alpha
Advocate for each unfilled Alpha Advocate position; provided, however, that
Talecris will reimburse CHR for reasonable expenses associated with covering
key business activities while a territory is open (e.g., travel expenses for
another Alpha Advocate to attend previously scheduled Alpha-I event in an open
territory).  CHR will utilize
commercially reasonable best efforts to fill any open Alpha Advocate positions
in a timely manner.  CHR and Talecris may
mutually agree at any time to increase or decrease the number of Alpha
Advocates.  [***]

 

(2)           [***]  Notwithstanding the foregoing, the following
provisions set forth the compensation arrangement between the parties [***]
first entered into on or after January 1, 2009.

 

(a)                                  With respect to
those [***] for which CHR provides it standard Services, the Standard Fees set
forth in this Agreement will apply.

 

(b)                                 With respect to
those [***] for which Talecris ships the Product direct to such [***] and the
[***] utilizes the Services of CHR to order individual patient shipments from
CHR (i.e., CHR has no direct contact or follow-up with patients), Talecris will
pay the Base Fee only.  An example of this
type of [***] is Kaiser, which became effective in October 2007.

 

(c)                                  With respect to
those [***] for which Talecris ships the Product direct to such [***] and the
[***] utilizes some or all of CHR’s enrollment Services, Talecris will pay CHR
the following monthly fee for the first six month period in the term of the
[***]:

 

[***]

 

After the first six months
in the term of the [***] for such [***], Talecris will pay CHR an enrollment
fee of $[***] for every new patient covered by such [***] who is registered in
the Prolastin Direct program available through the [***].  The enrollment fee will be paid in the month
immediately following the month in

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

which the patient is
registered in the Prolastin Direct program available through the [***].

 

(d)                                 With respect to
those [***] for which Talecris ships the Product direct to such [***] and the
[***] does not utilize any of CHR’s Services, Talecris will pay CHR the
following monthly fee for the first six month period in the term of the [***]:

 

[***]

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

EXHIBIT
C

 

ADDITIONAL
COMPENSATION

Prolastin DirectSM Program

 

In
addition to the compensation set forth on Exhibit B attached to
this Agreement, CHR will be eligible to receive additional fees per milligram
of Product shipped based on achieving key performance indictor (KPI) service
levels for Patient Loyalty and Patient Compliance.  CHR will invoice Talecris for any eligible
additional fees per milligram shipped each month up until defined Maximum
Annual Payment levels for additional payments are reached.  CHR will invoice Talecris for any additional
fees separately from the baseline fees described in Exhibit B.

 

If CHR meets KPI services levels of “High
Maintain” or greater during a calendar year, CHR will qualify for additional
per milligram fees in the subsequent calendar year.  Measurement criteria, Additional Fees per
milligram, and Maximum Annual Payments for Patient Loyalty and Patient
Compliance are defined below.  Talecris
will pay CHR additional per milligram fees in 2009 based on CHR achieving “High
Maintain” service levels for both Patient Loyalty and Patient Compliance in
2008.

 

The Additional Fees per milligram shipped, if
earned in a calendar year based on KPI service levels, will remain constant for
the term of this Agreement.  The Maximum
Annual Payment for additional fee payments based on KPI service level
achievement will be increased by CPI-U Adjustment as defined in Exhibit B,
which is used in calculating the annual adjustment to the base fee.

 

CHR
will also be eligible to receive KPI payments based on Days Sales Outstanding
(DSO) levels during a calendar year as defined below.  Talecris will pay any eligible DSO KPIs in January of
each calendar year with the first potential payment occurring in January 2010.

 

The KPI service levels will
be appropriately adjusted to account for any change [***]
that reduces the number of patients served by CHR so that CHR’s additional
payments will not be adversely affected. 
Each party will have the right to audit the other party’s books and
records with 14 days written notice to confirm KPI calculations and payments.

 

KPI
- Patient Loyalty.

 

This
KPI measures the number of Patients receiving Product in a calendar year as a
percentage of the Patients who received Product during the prior calendar
year.  Patient reductions due to death,
transplant, clinical study enrollment, or hospice are excluded from the
calculation [***]. The annual patient loyalty
KPI payment levels are set forth below, and the applicable measurement percentage
is determined by CHR as follows:

 

·                  [***]

 

·                  [***]

 

	
  Loyalty Level

  	
   

  	
  Additional

  Fee per Mg

  	
   

  	
  Maximum

  Annual Payment

  	
   

  	
  Measurement

  Percentage

  	
   

  
	
  Below

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Low Maintain

  	
   

  	
  —

  	
   

  	
  —

  	
   

  	
  [***

  	
  ]

  
	
  High Maintain

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Outstanding

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  

 

KPI
- Compliance.

 

This
KPI measures the “opportunity to ship” Product with the “actual shipments” of
Product during the calendar year.  The
calculation by CHR of the “opportunity to ship” Product will take into account
the prescribed frequency of infusions (for example, once-a-week) and strength
of the Product during the reporting period (e.g., the number of days for each
order available during the reporting period). 
The calculation by CHR of the “actual shipments” of Product will take

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

into
account the frequency and strength of the Product on orders actually shipped
during the reporting period.  The
applicable measurement percentage is determined by CHR as follows:

 

[***]

 

	
  Compliance

  Level

  	
   

  	
  Additional

  Fee per Mg

  	
   

  	
  Maximum

  Annual

  Payment

  	
   

  	
  Measurement

  Percentage

  	
   

  
	
  Below

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Low Maintain

  	
   

  	
  —

  	
   

  	
  —

  	
   

  	
  [***

  	
  ]

  
	
  High Maintain

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Outstanding

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  

 

Pro
forma Prolastin Base Fee plus Additional KPI (at “high maintain”) payments for
the Term of this Agreement are calculated below for illustrative purposes.  Payments in future year will be based on
actual milligrams shipped, CPI-U adjustments, and Additional Fees earned, if
any.

 

	
   

  	
   

  	
  2009

  	
   

  	
  2010

  	
   

  	
  2011

  	
   

  	
  2012

  	
   

  	
  2013

  	
   

  
	
  Milligrams (M)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  CPI-U Increase

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Fee/mg ($)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Fee Payment ($M)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Additional Fee/mg Loyalty
  ($)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Maximum Loyalty Payment
  ($M)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Additional Fee/mg
  Compliance ($)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Maximum Compliance Payment
  ($M)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  
	
  Total Payment ($)

  	
   

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  	
  [***

  	
  ]

  

 

KPI
- Days Sales Outstanding (DSO).

 

The
KPI for DSOs will be calculated on an average monthly basis at the end of each
calendar year.  DSOs will be calculated
based on the then current formula agreed to by both Talecris and CHR. [***]:

 

·                              Average < 50
days - CHR earns [***] per day below [***] days

·                              50 days <
Average <56 days - [***]

·                              56 days <
Average < 60 days - [***]

·                              60 days <
Average - CHR pays Talecris [***] per [***]

 

Certain
significant disruptions in accounts payable will be exempted from average DSO
calculations.  Exemptions will include
Payor insolvencies and documented government (e.g., Medicare and Medicaid)
payment freezes.  Exemptions will not include
delays caused by Payor actions such as billing system changes or mergers and
acquisitions.  Delays in payment caused
by documented changes in Payor billing systems (e.g., new enterprise software
systems) will be included in the DSO calculations.  However, CHR will not be penalized if such
Payor system changes cause average DSOs to rise above [***].
DSOs will be calculated by CHR at the end of each calendar year and any
applicable payments will be made in January of the following year.  The first DSO KPI payments under this
Agreement will be made in January 2010.

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

EXHIBIT
D

 

[***] PILOT PROGRAM

 

·                  CHR and
Talecris agree to jointly develop a [***] health management program for [***] (“[***]
Program”).  A component of the [***]
Program will include the design of a pilot test program to validate the health
management components.

 

·                  Development
costs will be shared equally, but the total value of Talecris’ share of the
development costs (including direct payments and in-kind services) will not
exceed $100,000.

 

·                  Once the design
of the [***] Program is completed, Talecris will have the first right to participate
with CHR in a pilot test of the [***] Program. 
Fees and other costs related to the pilot test will be determined by CHR
and Talecris once the design of the [***] Program is complete.

 

·                  If Talecris
declines to participate in the pilot test, or subsequent full implementation of
the [***] Program, CHR may market the program to other entities such as
payoffs, physician groups, or specialty pharmacies.  CHR must remove any data that is proprietary
to Talecris from the program prior to marketing it to other entities.  CHR will be responsible for reimbursing
Talecris for direct development costs incurred by Talecris if CHR successfully
commercializes the program with another entity. 
To the extent that [***] therapy is included as part of the [***] Program,
CHR must advocate [***] use that is consistent with indications listed in the
complete prescribing information of [***] products.  If Talecris declines to test or implement the
[***] Program, CHR may use the program design or other program content for
other immune disorder programs outside of [***].  CHR may not at any time market the [***]
Program to any other manufacturer of an [***] product.

 

·                  The parties
agreed that CHR will own the health management program content of the [***]
Program, but Talecris will have a perpetual, non-exclusive right to use
(independent of CHR) the content of the [***] Program in any form at no charge.  Nothing herein obligates CHR to provide any
services in connection with any such independent usage by Talecris.

 

·                  If a [***]
Program is successfully designed, tested, and implemented by the parties, CHR
and Talecris will be subject to exclusivity provisions with respect to the
program that are comparable in scope to the exclusivity provisions applicable
to the Alpha-1 program contained in Section 6.1 of this Agreement.

 

·                  The cost of the
pilot [***] Program, and any charges related to a fully implemented [***]
Program will be determined by the parties based on the final design of the
[***] Program.

 

·                  From and after
the formal launch of the [***] Program, except as otherwise agreed by the
parties in writing, the term “Services” as used in this Agreement will be
deemed to include services provided in connection with the [***] Program, the
term “Product” as used in this Agreement will be deemed to include the [***]
products supplied by Talecris

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

to
CHR in connection with the [***] Program, and the term “Patients” will be
deemed to include patients registered in the [***] Program; provided, however,
that Exhibits A, B and C of this Agreement will not apply to the [***]
Program.  All information, data and
materials relating to the [***] Program will be segregated from all
information, data and materials relating to all other health management
programs conducted by CHR.  Any
information about the [***] Program to be disclosed by CHR to Talecris shall be
disclosed only to a Program Manager designated in writing by Talecris and not
to any other Talecris employees.

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

EXHIBIT
E

 

BUSINESS
ASSOCIATE ADDENDUM

 

 

TALECRIS
BIOTHERAPEUTICS, INC.

 

and

 

CENTRIC
HEALTH RESOURCES, LLC

 

 

This
Business Associate Addendum (“Addendum”), effective January 1, 2009 (“Effective
Date”), is entered into by and between Centric Health Resources, LLC, on behalf
of itself and its affiliates (“CHR”) and Talecris Biotherapeutics, Inc. (“Talecris”)
(each a “Party” and collectively the “Parties”).

 

1.             BACKGROUND AND PURPOSE.  The Parties have entered into, and may in the
future from time to time enter into, one or more agreements, written or oral,
that require CHR to create, receive, maintain, use, disclose or transmit
Protected Health Information (“PHI”) or Electronic Protected Health Information
(“EPHI”) that is subject to the federal privacy regulations and security
regulations promulgated pursuant to the Health Insurance Portability and
Accountability Act (“HIPAA”) and codified at 45 C.F.R. parts 160, 162 and 164 (“HIPAA
Regulations”) (collectively, the “Underlying Contracts”).  This Addendum shall govern CHR’s creation,
receipt, maintenance, disclosure and transmission of such PHI or EPHI as a
Business Associate (as defined in HIPAA Regulations) of Talecris under the
Underlying Contracts.  It supplements
and/or amends the Underlying Contracts as necessary to allow Talecris to comply
with the HIPAA Regulations.  Except as
supplemented, amended and/or interpreted as set forth below, the terms of the
Underlying Contracts shall continue unchanged and shall apply with full force
and effect to govern the matters addressed in this Addendum and in the
Underlying Contracts.

 

2.             DEFINITIONS.  Unless otherwise defined in this Addendum,
all terms used in this Addendum have the meanings ascribed in the HIPAA
Regulations to the extent defined therein.

 

3.             OBLIGATIONS OF THE PARTIES WITH
RESPECT TO PHI.

 

3.1           Obligations of CHR.  With regard to its use and/or disclosure of
PHI, CHR agrees to:

 

a.             not use or further disclose
the PHI other than as permitted or required by this Addendum or as required by
law.

 

b.             use appropriate safeguards
to prevent use or disclosure of PHI other than as provided for by this
Addendum.  Without limiting the
generality of the foregoing sentence CHR will

 

 

(1)           Implement administrative,
physical, and technical safeguards that reasonably and appropriately protect
the confidentiality, integrity, and availability of EPHI as required by the
Security Rule;

 

(2)           Ensure that any agent,
including a subcontractor to whom CHR provides EPHI agrees, in writing, to
implement the same safeguards to protect EPHI as provided in subsection 3.1
b.(1); and

 

(3)           Report to Talecris any
Security Incident (as defined by the HIPAA Regulations) of which Business
Associate becomes aware.

 

c.             report to Talecris any use
or disclosure of PHI not provided for by this Addendum of which CHR becomes
aware.

 

d.             require any agent, including
any subcontractor, that receives, uses, or has access to PHI under the
Underlying Contracts to agree in writing to the same restrictions and
conditions on the use and/or disclosure of PHI that apply to CHR pursuant to Section 3.1
of this Addendum.

 

e.             to respond to Individual(s) request(s) for
access to PHI about them in accordance with HIPAA Regulations, to the extent
that such PHI is in the possession or control of CHR and is maintained in a
Designated Record Set (as such term is defined by CHR in accordance with HIPAA
regulations).

 

f.              make amendments to PHI when
requested by Individuals in accordance with the HIPAA Regulations, to the
extent that such PHI is in the possession or control of CHR and is maintained
in a Designated Record Set.

 

g.             document any and all
disclosures of PHI by CHR as well as any other information related to such
disclosures of PHI that would be required for CHR to respond to a request for
an accounting of disclosures made to Talecris or CHR in accordance with the
HIPAA Regulations.

 

h.             respond to requests to
Talecris or CHR for an accounting of disclosures documented in accordance with
subsection 3.1.g in accordance with HIPAA Regulations.

 

i.              make available upon request
by the Secretary of HHS any and all internal practices, books and records of
CHR relating to the use and disclosure of PHI, for purposes of determining
Talecris’s compliance with the HIPAA Regulations; provided, that before
responding to any such request by the Secretary, CHR shall provide Talecris
prompt and sufficient prior notice of any such request to enable Talecris to
seek and, when possible, obtain a protective order or otherwise take such
appropriate protective legal action as Talecris may deem necessary in its sole
discretion.

 

j.              return to Talecris or its
designee or destroy, within ninety (90) calendar days of the termination of
this Addendum with respect to any Underlying Contract, any

 

 

and all PHI in the
possession or control of CHR or its agents, including subcontractors, as a
result of the Underlying Contract at issue and retain no copies.  If such return or destruction of PHI is
mutually agreed by the parties to be infeasible, CHR agrees to (a) provide
written notification to Talecris of the conditions that make such return or
destruction infeasible and (b) for so long as CHR or its agents, including
subcontractors, maintain such PHI, (i) extend all protections contained in
this Addendum to the use and/or disclosure of any retained PHI by CHR or its
agents, including subcontractors and (ii) limit any further uses and/or
disclosures of such PHI by CHR or its agents, including subcontractors, to the
purposes that make the PHI’s return or destruction infeasible.

 

3.2           Permitted Uses and
Disclosures of PHI by CHR; Title to PHI.  Except as otherwise specified in this
Addendum, CHR may make any and all uses and disclosures of PHI necessary to
perform its obligations under the Underlying Contracts.  Unless otherwise limited by this Addendum,
CHR may (a) use the PHI in its possession for its proper management and
administration or to carry out the legal responsibilities of CHR; (b) disclose
the PHI in its possession to a third party for the purpose of CHR’s proper
management and administration or to carry out the legal responsibilities of
CHR, provided that the disclosures are required by law or that CHR has obtained
reasonable assurances from the third party to which PHI is to be disclosed
regarding the confidential handling of such PHI as required under the HIPAA
Regulations and the third party has agreed to notify CHR of any instances of
which it becomes aware in which the confidentiality of the information has been
breached; (c) provide Data Aggregation services relating to the Health Care
Operations of the Talecris as permitted by the I-HIPAA Regulations and (d) subject
to prior written approval by the Parties, de-identify any and all PHI obtained
by CHR under this Addendum at any location, and use such de-identified data,
all in accordance with the de-identification requirements of the HIPAA
Regulations.

 

Notwithstanding the
forgoing, as between Talecris and CHR, Talecris now and shall forever hold, and
CHR shall not hold and will not acquire by virtue of its performance of this
Addendum or the Underlying Contracts, all right, title and interest in and to
the PHI or any portion thereof. 
Furthermore, except as specified in this Agreement with Underlying
Contracts, CHR shall have no right to compile, aggregate and/or distribute such
PHI or any other health and medical data obtained from Talecris, or create or
distribute any analysis or report relating thereto.

 

3.3           Obligations of Talecris.  Talecris agrees to timely notify CHR of any
arrangements between Talecris and any Individual who is the subject of PHI that
may impact in any manner the use and/or disclosure of that PHI by CHR under
this Addendum.

 

3.4           Effect of Changes to the
HIPAA Regulations.  To the
extent that any relevant provision of the HIPAA Regulations is amended in a
manner that materially changes the obligations of Business Associates or
Covered Entities that are embodied in the terms of this Addendum, the Parties
agree to negotiate in good faith appropriate written amendment(s) to this
Addendum in order to give effect to these revised obligations.

 

 

4.             TERMINATION.  This Addendum shall terminate upon the
termination or expiration of the last of the Underlying Contracts.  Upon Talecris’s knowledge of a material
breach (as determined by Talecris in its sole discretion) of the terms of this
Addendum by CHR, Talecris shall provide CHR written notice of that breach in
sufficient detail to enable CHR to understand the specific nature of that
breach and afford CHR an opportunity to cure the breach.  If CHR fails to cure the breach within a
reasonable period of time specified by Talecris in its notice, Talecris may
immediately terminate this Addendum and the Underlying Contracts associated
with such breach.  Any termination
described herein shall give rise to CHR’s obligations set forth in Section 3.1.j.

 

5.             INDEMNIFICATION.  CHR shall defend, indemnify and hold harmless
Talecris, its officers, employees and agents from and against any and all
claims, damages, losses, liabilities, costs and expenses (including attorneys’
fees and costs) incurred by Talecris as a result of any third party claim
relating to or arising our of any breach or alleged breach by CHR of its
obligations under this Addendum.  The
foregoing shall be in addition to, and not in derogation of, any other rights
Talecris may have against CHR under this Addendum or otherwise at law or
equity.

 

6.             RIGHT TO INJUNCTIVE RELIEF.  CHR expressly acknowledges and agrees that
the breach, or threatened breach, by it of any provision of this Addendum may
cause Talecris irreparable harm and that Talecris will not have an adequate
remedy at law.  CHR therefore agrees that
Talecris may be entitled to injunctive relief to prevent such breach or
threatened breach, and hereby agrees not to oppose any attempt to obtain such
relief.  The foregoing shall be in
addition to, and not in derogation of, any other rights Talecris may have
against CHR under this Addendum or otherwise at law or equity.

 

7.             MISCELLANEOUS.

 

7.1           Interpretation.  This Addendum and the Underlying Contracts
(together with other Exhibits thereto) shall constitute the entire
understanding of the parties and supercedes, and its terms shall govern, all
prior and contemporaneous proposals, agreements or other communications between
the parties, oral or written, regarding such subject matter.  The terms of this Addendum shall prevail in
the case of any conflict with the terms of any Underlying Contract or Exhibit thereto.  In the event of an ambiguity or any
inconsistency between this Addendum and the provisions of the HIPAA Regulations,
as amended or interpreted by a court or regulatory agency with binding legal
authority over one or more of the parties, the HIPAA Regulations, as amended or
interpreted shall control.  Where the
provisions of this Addendum are different than or in addition to those mandated
by the HIPAA Privacy Regulations, but are nonetheless permitted or not
precluded by such Regulations, the provisions of this Addendum shall
control.  Notwithstanding anything in
this Addendum to the contrary, any “contrary” and “more stringent” provisions
of other health information privacy and security laws, rules or
regulations (as determined in accordance with HIPAA preemption rules set
forth at 45 C.F.R. 160.201, et seq.) shall prevail in the event of a conflict
between such provisions and those of this Addendum and/or the HIPAA
regulations.

 

7.2           Survival.  With respect to any Underlying Contract,
Sections 1, 2, 3.1.j, 4, 5, and 7 of this Addendum shall survive termination of
this Addendum and continue indefinitely solely

 

 

with respect to PHI that CHR
or its agents, including subcontractors, retain in accordance with Section 3.1.j.  Notwithstanding and in addition to the
forgoing, Section 5 and 6 of this Addendum shall survive termination of
this Addendum.

 

7.3           No Third Party Beneficiaries.  Except as set forth in Sections 3.1.i ,
nothing in this Addendum shall confer upon any person other than the Parties
and their respective successors or assigns, any rights, remedies, obligations,
or liabilities whatsoever.

 

[remainder
of page intentionally left blank]

 

 

IN WITNESS WHEREOF, each of the undersigned has caused this Addendum to
be executed in its name and on its behalf by its duly authorized
representative.

 

TALECRIS
BIOTHERAPEUTICS, INC. CENTRIC HEALTH RESOURCES, LLC

 

	
  By:

  	
  /s/ John Perkins

  	
   

  	
  By:

  	
  /s/ Craig L. Kephart

  
	
   

  	
   

  	
   

  
	
  Print Name: 

  	
  John R. Perkins

  	
   

  	
  Print Name: 

  	
  Craig L. Kephart

  
	
   

  	
   

  	
   

  
	
  Print Title:

  	
  SVP and General Manager Portfolio 

  	
   

  	
  Print Title:

  	
  CEO

  
	
   

  	
  Management and US Business

  	
   

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  By:

  	
  /s/ Charles Gayer

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Print Name:

  	
  Charles Gayer

  	
   

  	
   

  
	
   

  	
   

  	
   

  
	
  Print Title:

  	
  Senior Director, Pulmonary

  	
   

  	
   

  

 

 

EXHIBIT
F

 

DESIGNATED
EMPLOYEES

 

John
Walsh

Craig Kephart

Michelle Hefley

Tom Westrich

John Fielde

 

 

EXHIBIT
G

 

BUSINESS
CONTINUITY PLAN

 

Centric

health resources

 

Business Continuity Plan

 

 

Centric

health resources

 

Business Continuity Plan

 

Table of Contents

 

	
  1.0

  	
  Plan Overview

  	
  2

  
	
  2.0

  	
  Recovery Materials

  	
  2

  
	
  3.0

  	
  Alternate Facilities

  	
  3

  
	
  4.0

  	
  Program Inventory

  	
  3

  
	
  5.0

  	
  Technology

  	
  3

  
	
  6.0

  	
  Temporary Operations Preparation and Execution

  	
  3

  
	
  7.0

  	
  Annual Plan Testing

  	
  3

  

 

	
  Appendix A

  	
   

  	
  – Program Contact Lists

  
	
  Appendix B

  	
   

  	
  – Employee Contact List

  
	
  Appendix C

  	
   

  	
  – Supplier Contact List

  
	
  Appendix D

  	
   

  	
  – Technology Equipment & Supplies List

  
	
  Appendix E

  	
   

  	
  – Network Equipment List

  
	
  Appendix F

  	
   

  	
  – Program Telecom List

  
	
  Appendix G

  	
   

  	
  – Software Applications List

  
	
  Appendix H

  	
   

  	
  – Telecom Capacity list

  
	
  Appendix I

  	
   

  	
  – Office Supplies List

  
	
  Appendix J

  	
   

  	
  – State Boards of Pharmacy Contact List

  
	
  Appendix K

  	
   

  	
  – Pharmacy Operations Equipment & Supplies List

  
	
  Appendix L

  	
   

  	
  – Emergency Script

  
	
  Appendix M

  	
   

  	
  – Manual Resource Documents

  

 

 

Centric

health resources

 

Business Continuity Plan

 

1.0           Plan Overview

1.1       This plan overview outlines the tools and resources
maintained by Centric Health Resources, Inc. (CHR) to ensure continued
program operations during any facility and/or system outage.  Outages are defined as Centric facility
and/or CPR+ system unavailable.

 

1.2       The components of the plan have been segmented as
follows:

1.2.1        Recovery
Materials

1.2.2        Alternate
Facilities

1.2.3        Program
Inventory

1.2.4        Technology

1.2.5        Temporary
Operations Preparation and Execution

1.2.6        Annual
Plan Testing

1.2.7        Appendices

 

1.3       Each component of the plan stands alone and can be
used exclusively or in combination to meet the requirements of the applicable business
outage.

 

2.0           Recovery Materials

2.1       Recovery materials are maintained (online and
hardcopy) and stored off-site to be available during any business outage:

2.1.1        Emergency-preparedness
plan: A separate plan that immediate action is taken at the time of any
business outage to protect company, employee and client interests.  Refer to CMS-2-15 for more information.

2.1.2        Business
continuity project plan: A plan that identifies all processes,
responsibilities, and resources required for the “worst case scenario” business
outage.  This is documented on RD-2-15e,
Business Continuity Plan Checklist.

2.1.3        Appendices:
A set of lists that include program contacts, equipment and supply lists,
manual forms for program administration, etc.:

2.1.3.1             A: Program contact list

2.1.3.2             B: Employee contact list

2.1.3.3             C: Vendor contact list

2.1.3.4             D: Technology equipment/supplies list

2.1.3.5             E: Network Equipment List

2.1.3.6             F: Program telecom list

2.1.3.7             G: Software applications list

2.1.3.8             H: Telecom capacity list

2.1.3.9             I : Office supplies list

2.1.3.10           J: State boards of pharmacy contact list

2.1.3.11           K: Pharmacy operations equipment/supplies list

2.1.3.12           L: Emergency Script

2.1.3.13           M: Manual forms

 

 

3.0           Alternate Facilities

3.1       In the case of a business disruption, CHR staff would
be relocated to alternate facilities based on functional area.  Each alternate facility will meet the minimum
requirements to ensure that program operations are sustained.

 

3.2       CHR senior management has secured the Foundation Care,
Earth City pharmacy location to transfer pharmacy operations when the current
facility pharmacy becomes inaccessible for more than 5 business days.  The available pharmacy space meets the
following minimum requirements:

3.2.1        Temperature
controlled (heat/air conditioning)

3.2.2        Work
space for pick/pack/ship activities

3.2.3        Work
tables and shelving units for shipping equipment and supplies 3.2.4 Entry ways
to allow pallets of material

 

3.3       CHR senior management has secured the Hosterian site
to transfer reimbursement and nursing operations when the current office
facility becomes inaccessible for more than 5 business days.  The available office space meets the
following minimum requirements:

3.3.1        Continuous
power supply with back-up generator

3.3.2        Work
space for patient intake/insurance verification/authorization/reimbursement
activities

3.3.3        Work
tables and shelving units for office equipment and supplies

 

4.0           Program Inventory

4.1       All drug inventory requiring refrigeration will be
stored between 2-25 degrees C in a refrigerated truck(s) from Skelton
Truck Lines, or other client approved carriers, with a designated quarantine
area (segregated and locked).  Program
supplies and shipping materials will be stored in the alternate facility and/or
rented trucks.

 

5.0           Technology

5.1       All CHR data is backed up offsite to Recall’s Data
Protection Services each business day. 
The backups are “complete” vs. 
incremental and verified on a nightly basis.  This data includes business data (documents,
spreadsheets, emails, digital fax images, etc), CPR+ patient and pharmacy data,
and all call system data, including voice mails.

 

6.0           Temporary Operations Preparation and Execution

6.1       Once the parameters of the business outage have been
established, temporary operations are conducted to continue patient care.  The Business Continuity Plan Checklist,
RD-2-15e, is referenced to extract the applicable line items necessary to carry
out temporary program operations; beginning with outage notification to staff
deployment and training to the delivery of product and services to program
patients to program restoration.

 

7.0           Annual Plan Testing

7.1       Each calendar year, the approved business continuity
plan will be tested via a “table top” simulation for the “worst case scenario”
business outage in which the current facility and inventory are completely
destroyed.  The test exercise will be
scheduled with all program participants via conference call.  A program representative from Centric will be
located at each of the following sites to confirm adequate resources and
readiness in the event of an actual business outage:

 

 

8.0           Centric Health Resources: senior program management

8.1       Client facility: logistics, quality assurance and/or
temperature validation management for inventory replenishment and storage
capacity

8.2       Foundation Care, Earth City facility: IT for
connectivity

8.3       Hosterian alternate facility: IT for connectivity

 

8.4       The scenario will be developed by Centric Health
Resources senior management and distributed to each participant at the
beginning of the test exercise.  The
scenario will be executed to its fullest extent, given technology and
logistical capabilities, but will at a minimum verify the following:

8.4.1        Current
business continuity plan exists

8.4.2        Current
contact information for all staff, regulatory agencies, business partners,
vendors, etc. exist

8.4.3        Current
supply and equipment lists exist

8.4.4        Alternate
facility minimum requirements exist

8.4.5        Technology
minimum requirements are functional

8.4.6

8.5       Any deficiencies found during the test exercise are
documented on RD-2-15e and the business continuity plan is re-worked to resolve
any flaws and presented to program management within 30 business days for
review and/or approval as required.

 

 

Appendix A:  Program Contact Lists

 

[*** List of sixteen (16)
program contacts]

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Appendix B: Employee Contact List

 

[*** List of eighty-six
(86) employee contacts]

 

*** CONFIDENTIAL TREATMENT REQUESTED

 

 

Appendix C: Supplier Contact List

 

[*** List of forty-one
(41) supplier contacts]

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Appendix D: Technology Equipment &
Supplies List

 

[*** List of six
(6) computers]

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Appendix E: Network Equipment List

 

[*** List of seven
(7) network products]

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Appendix F: Program Telecom List

 

	
  Number

  	
   

  	
  Associated
  With

  	
   

  	
  Vendor

  
	
  866.849.4481

  	
   

  	
  Centric Health Resources

  	
   

  	
  Qwest

  
	
  800.305.7881

  	
   

  	
  Talecris Direct

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Centric Health Resources

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Centric Health Resources

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Charis Partners

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Nemours

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Apotex (Hepagam)

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Compliance Hotline

  	
   

  	
  Qwest

  
	
  [***]

  	
   

  	
  Employee Hotline

  	
   

  	
  Qwest

  

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Appendix G: Software Applications List

 

Software List

 

	
   

  	
  1.

  	
  Adobe Acrobat
  7.0 Standard - Windows Edition

  
	
   

  	
  2.

  	
  Microsoft
  Exchange Server 2003 Standard

  
	
   

  	
  3.

  	
  Microsoft
  Windows Server 2003 Standard Edition

  
	
   

  	
  4.

  	
  Computer
  Associates eTrust Antivirus 8.1

  
	
   

  	
  5.

  	
  Microsoft SQL
  Server 2000 Standard Edition

  
	
   

  	
  6.

  	
  Microsoft Office
  Small Business Edition 2003 wISP2

  
	
   

  	
  7.

  	
  HP MS OFFICE
  2003 PRO

  
	
   

  	
  8.

  	
  HP MS OFFICE
  2003

  
	
   

  	
  9.

  	
  QuickBooks
  Premier Editions 2008 Win 5-user

  
	
   

  	
  10.

  	
  MLF PROJECT 2003
  WIN32

  
	
   

  	
  11.

  	
  EXCHANGE SVR
  2003 ENG

  
	
   

  	
  12.

  	
  VISIO STD 2003
  ENG BUS-6.0

  
	
   

  	
  13.

  	
  Office Project
  Professional 2003

  
	
   

  	
  14.

  	
  ACCESS 2003 ENG
  BUS-6.0

  
	
   

  	
  15.

  	
  VERITAS Backup
  Exec for Windows Servers - ( v. 10.0) - media

  
	
   

  	
  16.

  	
  BACKUP EXEC 10D
  WIN MS EXCHANGE

  
	
   

  	
  17.

  	
  CPR+

  
	
   

  	
  18.

  	
  PRTG v5.1.1.474

  
	
   

  	
  19.

  	
  Call Manager

  
	
   

  	
  20.

  	
  IPCC

  
	
   

  	
  21.

  	
  Unity Voicemail

  
	
   

  	
  22.

  	
  Citrix
  Presentation Server

  
	
   

  	
  23.

  	
  CentricDTS -
  Discrepancy Tracking System

  
	
   

  	
  24.

  	
  CentricConnect -
  Ticket Tracking System

  

 

 

Appendix H: Telecom Capacity List

 

	
  Vendor/Usage

  	
   

  	
  Owner

  	
   

  	
  Capacity

  
	
  Qwest/LD

  	
   

  	
  Centric Health Resources

  	
   

  	
  T-1

  
	
  Qwest/LD

  	
   

  	
  Centric Health Resources

  	
   

  	
  T-1

  
	
  Qwest/LD

  	
   

  	
  Centric Health Resources

  	
   

  	
  T-1

  
	
  Qwest/LD

  	
   

  	
  Centric Health Resources

  	
   

  	
  T-1

  
	
  SBC/Local Loop

  	
   

  	
  Centric Health Resources

  	
   

  	
  T-1/10 Trunks

  

 

 

Appendix I: Office Supplies List

 

Office
Depot

https://bsd.officedepot.com/index/do

Login
name: [***]

Password:
[***]

Contact:  Sheila Swanson, Account Manager

[***]

[***]

[***]

2977
Hwy K #145

O’Fallon,
MO 63368

 

Regency
Office Products

http://www.regencyofficeproducts.com/

Username:
[***]

Password:
[***]

Contact:  Melissa Maniaci

[***]

[***]

130
S. Bemiston Ave., Ste. 700

St.
Louis, MO 63105

 

	
  Supply

  	
   

  	
  Phase I

  	
   

  	
  Phase II

  	
   

  	
  Regency Office

  	
   

  	
  Office Depot

  	
   

  	
  Notes

  	
   

  
	
  Ink
  pens

  	
   

  	
  5 dozen

  	
   

  	
  3 dozen

  	
   

  	
  PENBK440A

  	
   

  	
  120675

  	
   

  	
   

  	
   

  
	
  Calculators

  	
   

  	
  30 each

  	
   

  	
  30 each

  	
   

  	
  VCT12082

  	
   

  	
  569771

  	
   

  	
   

  	
   

  
	
  Stapler

  	
   

  	
  30 each

  	
   

  	
  30 each

  	
   

  	
  SWI74701

  	
   

  	
  655324

  	
   

  	
   

  	
   

  
	
  Tape
  w/dispenser

  	
   

  	
  30 each

  	
   

  	
  30 each

  	
   

  	
  MMM105

  	
   

  	
  473592

  	
   

  	
   

  	
   

  
	
  White
  paper

  	
   

  	
  3 cases

  	
   

  	
  4 cases

  	
   

  	
  REG21200

  	
   

  	
  348037

  	
   

  	
   

  	
   

  
	
  Patient
  file

  	
   

  	
  1200

  	
   

  	
  1400

  	
   

  	
  SJPS60447

  	
   

  	
  307959

  	
   

  	
   

  	
   

  
	
  Manila
  folders

  	
   

  	
  1200

  	
   

  	
  1400

  	
   

  	
  SPRSP11113

  	
   

  	
  367671

  	
   

  	
   

  	
   

  
	
  Hanging
  folders

  	
   

  	
  1200

  	
   

  	
  1400

  	
   

  	
  SMD64239

  	
   

  	
  314310

  	
   

  	
   

  	
   

  
	
  Paper
  clips

  	
   

  	
  10 boxes

  	
   

  	
  25 boxes

  	
   

  	
  ACC72385

  	
   

  	
  308478

  	
   

  	
   

  	
   

  
	
  Federal
  Express

  	
   

  	
  2 case

  	
   

  	
  3 cases

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Fedex.com

  	
   

  
	
  Federal
  Express 

  	
   

  	
  100 each

  	
   

  	
  200 each

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  Fedex.com

  	
   

  
	
  Filing
  Cabinets 

  	
   

  	
  3

  	
   

  	
  4

  	
   

  	
  HOM 695L

  	
   

  	
  989368

  	
   

  	
   

  	
   

  
	
  HCFA
  1500 Forms

  	
   

  	
  2 box

  	
   

  	
  3 boxes

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PMIC-John Santiago [***] 

  ext. [***] account # [***]

  	
   

  

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

	
  Supply

  	
   

  	
  Phase I

  	
   

  	
  Phase II

  	
   

  	
  Regency Office

  	
   

  	
  Office Depot

  	
   

  	
  Notes

  	
   

  
	
  UB92
  Forms

  	
   

  	
  200

  	
   

  	
  200

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PMIC-John Santiago [***] ext. [***] account #[***]

  	
   

  
	
  ICD-9
  Code book

  	
   

  	
  1

  	
   

  	
  —

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PMIC-John Santiago [***]ext. [***] account # [***]

  	
   

  
	
  HCPC
  Code book

  	
   

  	
  1

  	
   

  	
  —

  	
   

  	
   

  	
   

  	
   

  	
   

  	
  PMIC-John Santiago [***]ext. [***] account # [***]

  	
   

  
	
  Envelopes,
  regular

  	
   

  	
  2 box

  	
   

  	
  3 boxes

  	
   

  	
  SPR09099

  	
   

  	
  348201

  	
   

  	
   

  	
   

  
	
  Envelopes,
  HCFA window

  	
   

  	
  2 box

  	
   

  	
  3 boxes

  	
   

  	
  QUA21 332

  	
   

  	
  423244

  	
   

  	
   

  	
   

  
	
  Glue
  Sticks

  	
   

  	
  30

  	
   

  	
  30

  	
   

  	
  AVE00196

  	
   

  	
  571121

  	
   

  	
   

  	
   

  
	
  Mailing
  labels

  	
   

  	
  1 box

  	
   

  	
  1 box

  	
   

  	
  AVE00196

  	
   

  	
  364380

  	
   

  	
   

  	
   

  
	
  File
  Folder labels

  	
   

  	
  2 boxes

  	
   

  	
  2 boxes

  	
   

  	
  AVE05366

  	
   

  	
  220424

  	
   

  	
   

  	
   

  
	
  Box
  cutters

  	
   

  	
  24 pack

  	
   

  	
  —

  	
   

  	
  PHCHC100

  	
   

  	
  946210

  	
   

  	
   

  	
   

  
	
  Highlighters

  	
   

  	
  30

  	
   

  	
  35

  	
   

  	
  AVE17752

  	
   

  	
  812263

  	
   

  	
   

  	
   

  
	
  Post-it
  notes

  	
   

  	
  30

  	
   

  	
  35

  	
   

  	
  MM654YW

  	
   

  	
  639088

  	
   

  	
   

  	
   

  
	
  Computer
  paper (2-part)

  	
   

  	
  1 box

  	
   

  	
  1 box

  	
   

  	
  SPR01385

  	
   

  	
  437459

  	
   

  	
   

  	
   

  
	
  Staples

  	
   

  	
  3 boxes

  	
   

  	
  3 boxes

  	
   

  	
  SW1 S50050

  	
   

  	
  749601

  	
   

  	
   

  	
   

  
	
  Scissors

  	
   

  	
  30

  	
   

  	
  30

  	
   

  	
  SPRO2041

  	
   

  	
  375667

  	
   

  	
   

  	
   

  
	
  Envelopes
  9 x 12”

  	
   

  	
  1 box

  	
   

  	
  1 box

  	
   

  	
  SPR008890

  	
   

  	
  341081

  	
   

  	
   

  	
   

  
	
  Writing
  pads

  	
   

  	
  25

  	
   

  	
  30

  	
   

  	
  SPR2011

  	
   

  	
  305706

  	
   

  	
   

  	
   

  
	
  Staple
  remover

  	
   

  	
  25

  	
   

  	
  30

  	
   

  	
  SW138101

  	
   

  	
  427111

  	
   

  	
   

  	
   

  
	
  HP
  LaserJet 1012 (desktop)

  	
   

  	
  3

  	
   

  	
  3

  	
   

  	
  HEWQ2612A

  	
   

  	
  154414

  	
   

  	
   

  	
   

  
	
  OKI
  (color)

  Yellow

  Magenta 

  Cyan 

  Black-

  	
   

  	
   

  1 each

  	
   

  	
   

  —

  	
   

  	
   

  OK142127401 OK142127402 OK142127403 OK142127404

  	
   

  	
   

  379927 379873

  379864 378145

  	
   

  	
   

  	
   

  
	
  Matrix
  printer ribbon

  	
   

  	
  3

  	
   

  	
  5

  	
   

  	
  0K1152106001

  	
   

  	
  900639

  	
   

  	
   

  	
   

  
	
  HP
  LaserJet

  	
   

  	
  4

  	
   

  	
  4

  	
   

  	
  HEWQ5949A

  	
   

  	
  HEWQ5949A

  	
   

  	
   

  	
   

  
	
  HP
  LaserJet

  	
   

  	
  1

  	
   

  	
  1

  	
   

  	
  HEWQ7553A

  	
   

  	
  HEWQ7553A

  	
   

  	
   

  	
   

  

 

*** CONFIDENTIAL TREATMENT
REQUESTED

 

 

Appendix
J: State Boards of Pharmacy Contacts List

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  Alabama

  	
   

  	
  Alabama
  State Board of Pharmacy

  10 Inverness Center, Suite 110

  Birmingham, AL 35242

  205-981-2280

  	
   

  	
  112657/201372

  	
   

  	
  193222

  
	
  Alaska

  	
   

  	
  Alaska
  Division of Occupational Licensing

  Board of Pharmacy

  PO Box 110806

  Juneau, AK 99806

  907-465-2589

  	
   

  	
  739

  	
   

  	
  NIA

  
	
  Arizona

  	
   

  	
  Arizona
  State Board of Pharmacy

  1700 W. Washington Street

  Suite 250

  Phoenix, AZ 85007

  (602) 771-2727

  	
   

  	
  4451

  	
   

  	
  1302

  
	
  Arkansas

  	
   

  	
  Arkansas
  State Board of Pharmacy

  101 East Capitol, Suite 218

  Little Rock, AR 72201

  501-682-0190

  	
   

  	
  OS02034

  	
   

  	
  WD03128

  
	
  California

  	
   

  	
  California
  State Board of Pharmacy

  1625 N. Market Blvd., Suite N-219

  Sacramento, CA 95834

  916-574-7912

  	
   

  	
  NRP-758

  	
   

  	
  pending

  
	
  Colorado

  	
   

  	
  Department
  of Regulatory Agencies

  Colorado State Board of Pharmacy

  1560 Broadway, Suite 1350

  Denver, CO 80202

  303-894-7800

  	
   

  	
  5578

  	
   

  	
  7247

  
	
  Connecticut

  	
   

  	
  State
  of Connecticut

  Department of Consumer Protection

  License Services Division

  165 Capitol Avenue

  Hartford, CT 06106

  860-713-6070

  	
   

  	
  703

  	
   

  	
  CSW.0001801

  
	
  Delaware

  	
   

  	
  Delaware
  State Board of Pharmacy

  861 Silver Lake Blvd.

  Cannon Bldg., Suite 203

  Dover, DE 19904

  302-744-4526

  	
   

  	
  A9-0000607

  	
   

  	
  A4-00001307

  

 

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  District
  of Columbia

  	
   

  	
  D.C.
  Department of Health

  Health Regulation Administration

  825 North Capitol Street, NE Room 2224

  Washington, D.C. 20002

  202-535-2076

  	
   

  	
  N/A

  	
   

  	
  DM0500844

  
	
  Florida

  	
   

  	
  Florida Board of Pharmacy

  4052 Bald Cypress Way, Bin C-04

  PO Box 6330

  Tallahassee, FL 32314-6330

  850-245-4292  

  AND

  Florida Department of Health

  Bureau of Statewide Pharmaceutical Services

  2818-A Mahan Drive

  Tallahassee, FL 32308

  850-245-4292

  	
   

  	
  PH21254/26633

  	
   

  	
  pending

  
	
  Georgia

  	
   

  	
  Georgia
  State Board of Pharmacy

  237 Coliseum Drive

  Macon, GA 31217-3858

  478-207-2440

  	
   

  	
  N/A

  	
   

  	
  PHWH002145

  
	
  Hawaii

  	
   

  	
  Hawaii Board of Pharmacy

  DCCA, PVL Licensing BR

  335 Merchant SL, Room 301

  Honolulu, HI 96813

  OR

  PO Box 3469

  Honolulu, HI 96801

  808-586-3000

  	
   

  	
  PMP 551

  	
   

  	
  NIA

  
	
  Idaho

  	
   

  	
  Idaho
  State Board of Pharmacy

  3380 Americana Terrace, Suite 320

  Boise, ID 83706

  208-334-2356

  	
   

  	
  2015MS

  	
   

  	
  W2969

  
	
  Illinois

  	
   

  	
  Department
  of Financial and Professional

  Regulation

  ATTN: Division of Professional Regulation

  320 W. Washington Street, 3rd Floor

  Springfield, IL 62786

  217-782-8556

  	
   

  	
  054-0154828

  	
   

  	
  004.002307

  
	
  Indiana

  	
   

  	
  Indiana
  Board of Pharmacy

  402 West Washington Street, Room W072

  Indianapolis, IN 46204

  317-234-2067

  	
   

  	
  64000652A

  	
   

  	
  pending

  

 

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  Iowa

  	
   

  	
  Iowa
  Board of Pharmacy Examiners

  400 S.W. Eighth Street, Suite E

  Des Moines, IA 50309-4688

  515-281-5944

  	
   

  	
  3598

  	
   

  	
  6315

  
	
  Kansas

  	
   

  	
  Kansas
  State Board of Pharmacy

  Landon State Office Building

  900 Jackson, Room 560

  Topeka, KS 66612

  785-296-4056

  	
   

  	
  22-02403

  	
   

  	
  5-02042

  
	
  Kentucky

  	
   

  	
  Kentucky
  Board of Pharmacy

  Spindletop Administration Bldg., Suite 302

  2624 Research Park Dr.

  Lexington, KY 40511

  859-246-2820

  	
   

  	
  M01195

  	
   

  	
  W01896

  
	
  Louisiana

  	
   

  	
  Louisiana
  Board of Pharmacy

  5615 Corporate Blvd., Suite 8-E

  Baton Rouge, LA 70808-2537

  225-925-6496

  AND

  Louisiana
  Board of Wholesale Drug Distributors

  12046 Justice Avenue, Suite C

  Baton Rouge, LA 70816

  225-295-8567

  	
   

  	
  5636

  	
   

  	
  5166

  
	
  Maine

  	
   

  	
  Maine
  Department of Professional and Financial

  Regulation

  Office of Licensing and Registration

  35 State House Station

  Augusta, ME 04333-0035

  207-624-8603

  	
   

  	
  MO40000716

  	
   

  	
  WH70001210

  
	
  Maryland

  	
   

  	
  Maryland
  Board of Pharmacy

  4201 Patterson Avenue

  Baltimore, MD 21215

  410-764-4755, 800-542-4964

  	
   

  	
  P04405

  	
   

  	
  D01938

  
	
  Massachusetts

  	
   

  	
  Commonwealth
  of Massachusetts

  Board of Registration in Pharmacy

  239 Causeway Street, 2nd Floor, Suite 200

  Boston, MA 02114

  617-973-0950

  	
   

  	
  N/A

  	
   

  	
  N/A

  
	
  Michigan

  	
   

  	
  Michigan
  Department of Community Health

  Board of Pharmacy

  611 W Ottawa, First Floor

  PO Box 30670

  Lansing, MI 48909

  517-335-0918

  	
   

  	
  5301008389

  	
   

  	
  5306002494

  

 

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  Minnesota

  	
   

  	
  Minnesota Board of Pharmacy

  2829 University Avenue SE, #530

  Minneapolis, MN 55414-3251

  651-201-2825

  	
   

  	
  262741-0

  	
   

  	
  361707-6

  
	
  Mississippi

  	
   

  	
  Mississippi State Board of Pharmacy

  204 Key Drive, Suite D

  Madison, MS 39110

  OR

  PO Box 24507

  Jackson, MI 39225-4507

  601-605-5388

  	
   

  	
  06619/07.1

  	
   

  	
  06676/06.2

  
	
  Missouri

  	
   

  	
  Missouri State Board of Pharmacy

  3605 Missouri Blvd.

  Jefferson City, MO 65109

  OR

  PO Box 625

  Jefferson City, MO 65102

  573.751.0091

  	
   

  	
  2005040240

  	
   

  	
  2005041054

  
	
  Montana

  	
   

  	
  Montana State Board of Pharmacy

  301 South Park, 4th Floor

  PO Box 200513

  Helena, MT 59620-0513

  406-841-2371

  	
   

  	
  2022

  	
   

  	
  2023

  
	
  Nebraska

  	
   

  	
  Nebraska Board of Pharmacy

  301 Centennial Mall South

  PO Box 94986

  Lincoln, NE 68509

  402-471-2118

  	
   

  	
  460

  	
   

  	
  pending

  
	
  Nevada

  	
   

  	
  Nevada State Board of Pharmacy

  431 W Plumb Ln

  Reno, NV 89509

  775-850-1440

  	
   

  	
  PH02040

  	
   

  	
  WH01311

  
	
  New Hampshire

  	
   

  	
  State of New Hampshire

  Board of Pharmacy

  57 Regional Drive

  Concord, NH 03301-8518

  603-271-2350

  	
   

  	
  NR0443

  	
   

  	
  4467

  
	
  New Jersey

  	
   

  	
  New Jersey Department of Health and Senior

  Services

  Consumer and Environmental Health Services

  PO Box 369

  Trenton, NJ 08625-0369

  	
   

  	
  N/A

  	
   

  	
  5003347

  

 

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  New Mexico

  	
   

  	
  New Mexico Board of Pharmacy

  5200 Oakland NE, Suite A

  Albuquerque, NM 87113

  505-222-9830

  	
   

  	
  PH00002916

  	
   

  	
  WD00010727

  
	
  New York

  	
   

  	
  NY State Education Department

  Office of the Professions

  Division of Professional Licensing Services

  Fee Section/Pharmacy Unit

  89 Washington Avenue

  Albany, New York 12234-1000

  518-474-3817

  	
   

  	
  027856

  	
   

  	
  027855

  
	
  North Carolina

  	
   

  	
  North Carolina Board of Pharmacy

  PO Box 4560

  Chapel Hill, NC 27515-4560

  919-246-1050

  AND

  North Carolina Department of Agriculture &

  Consumer Services

  Food and Drug Protection Division

  1070 Mail Service Center

  Raleigh, NC 27699-1070

  919-733-7366

  	
   

  	
  09290

  	
   

  	
  448

  
	
  North Dakota

  	
   

  	
  North Dakota State Board of Pharmacy

  1906 E. Broadway

  Bismarck, ND 58501

  OR

  PO Box 1354

  Bismarck, ND 58502-1354

  701-328-9535

  	
   

  	
  667

  	
   

  	
  522

  
	
  Ohio

  	
   

  	
  Ohio State Board of Pharmacy

  77 South High Street, Room 1702

  Columbus, OH 43215-6126

  614-466-4143

  	
   

  	
  02-1612900

  	
   

  	
  01-1612950

  
	
  Oklahoma

  	
   

  	
  Oklahoma State board of Pharmacy

  4545 Lincoln Blvd., Suite 112

  Oklahoma City, OK 73105-3488

  405-521-3815

  	
   

  	
  99-964

  	
   

  	
  8-W-1566

  
	
  Oregon

  	
   

  	
  Oregon Board of Pharmacy

  800 NE Oregon St, Suite 150

  Portland, OR 97232

  971-673-0001

  	
   

  	
  RP-0002257

  	
   

  	
  W1-0002792

  

 

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  Pennsylvania

  	
   

  	
  Pennsylvania Department of Health

  Drug & Device Registration Section

  132 Kline Plaza, Suite A

  Harrisburg, PA 17104

  717-787-4779

  	
   

  	
  N/A

  	
   

  	
  8000001706

  (Wholesaler/ distributor)

  
	
  Rhode Island

  	
   

  	
  Rhode Island Department of Health

  Board of Pharmacy

  3 Capitol Hill - Room 205

  Providence, RI 02908-5097

  401-222-2840

  	
   

  	
  PHN09700

  	
   

  	
  DIS01586

  
	
  South Carolina

  	
   

  	
  South Carolina LLR - Board of Pharmacy

  110 Centerview Drive, Suite 306

  PO Box 11927

  Columbia, SC 29211-1927

  803-896-4700

  	
   

  	
  6008700

  	
   

  	
  70008699

  
	
  South Dakota

  	
   

  	
  South Dakota Board of Pharmacy

  4305 S. Louise Ave, Suite 104

  Sioux Falls, SD 57106

  605-362-2737

  	
   

  	
  400-0572

  	
   

  	
  600-1130

  
	
  Tennessee

  	
   

  	
  Tennessee Board of Pharmacy

  227 French Landing, Suite 300

  Nashville, TN 37243

  615-741-2718

  	
   

  	
  4187

  	
   

  	
  2271

  
	
  Texas

  	
   

  	
  Texas State Board of Pharmacy

  333 Guadalupe Street, Ste. 3-600

  Austin, Texas 78701

  512-305-8000

  AND

  Texas Department of State Health Services l100

  West 49th Street

  Austin, TX 78756

  OR

  PO Box 12008

  Austin, TX 78711

  512-719-0246

  	
   

  	
  25147

   

  	
   

  	
  0089718

   

  
	
  Utah

  	
   

  	
  Utah Division of Occupational & Professional

  Licensing

  160 East 300 South, 1st Floor Lobby

  Salt Lake city, UT 84111

  OR

  PO Box 146741

  Salt Lake City, UT 84114-6741

  801-530-6179

  	
   

  	
  6119996-1708

   

  	
   

  	
  NIA

   

  

 

 

	
  State

  	
   

  	
  Contact Information

  	
   

  	
  Pharmacy

  License

  Number

  	
   

  	
  Wholesale /

  Distributor

  License Number

  
	
  Vermont

  	
   

  	
  Office of Professional Regulation

  Vermont Board of Pharmacy

  National Life Bldg, North FL2

  Montpelier, VT 05620-3402

  802-828-2373

  	
   

  	
  036-0000216

   

  	
   

  	
  039-0001050

   

  
	
  Virginia

  	
   

  	
  Virginia Board of Pharmacy

  9960 Mayland Drive, Suite 300

  Richmond, VA 23233-1463

  804-367-4456

  	
   

  	
  214000909

   

  	
   

  	
  219000909

   

  
	
  Washington

  	
   

  	
  Washington State Department of Health

  Health Professions Quality Assurance

  310 Israel Rd.

  Tumwater WA 98501

  OR

  PO Box 47863

  Olympia, WA 98504-7863

  360-236-4825

  	
   

  	
  FM0058622

   

  	
   

  	
  FX00058618

   

  
	
  West Virginia

  	
   

  	
  West Virginia Board of Pharmacy

  232 Capitol Street

  Charleston, WV 25301

  304-558-0558

  	
   

  	
  MO0559792

  	
   

  	
  WD0558222

  
	
  Wisconsin

  	
   

  	
  Wisconsin Department of Regulation &

  Licensing1400 E. Washington Avenue

  Madison, WI 53703

  OR

  PO Box 8935

  Madison, WI 53708-8935

  608-266-2112

  	
   

  	
  188-043

  	
   

  	
  1964-045

  
	
  Wyoming

  	
   

  	
  Wyoming State Board of Pharmacy

  632 South David Street

  Casper, WY 82601

  307-234-0294

  	
   

  	
  NR50076

  	
   

  	
  2387

  
	
  DEA Certificate of Registration

  	
   

  	
  United States Department of Justice

  Drug Enforcement Administration

  Central Station

  PO Box 530295

  Atlanta, GA 30348-0295

  (314) 538-4600 (St. Louis office)

  (202) 307-1000 (D.C. office)

  	
   

  	
  BC9591202

  	
   

  	
  N/A

  

 

 

Appendix K: Pharmacy Operations Equipment/Supplies List

 

	
  Item Description

  	
   

  	
  Re-order
  number

  	
   

  	
  Quantity

  
	
  Global Industrial Equipment (800)231-3538 Acct # 63005CENT0001

  
	
  Pallet Shelving - Interlake Brand

  	
   

  	
   

  	
   

  	
   

  
	
  - Uprights - 12’ x 42”
  (ea)

  	
   

  	
  WQ347118

  	
   

  	
  6

  
	
  - L Beams - 8’ (pr)

  	
   

  	
  WQ347105

  	
   

  	
  12

  
	
  - Wire mesh shelving w/
  support (42” x 46”) (ea)

  	
   

  	
  WB979101

  	
   

  	
  24

  
	
  Pallet Jack 6600 lbs (ea)

  	
   

  	
  WQ585354

  	
   

  	
  1

  
	
  RIVET-LOCK Boltless Shelving wl Wood Deck

  	
   

  	
  WB601889

  	
   

  	
  10

  
	
  Wire Mesh carting (Nexel)

  	
   

  	
   

  	
   

  	
   

  
	
  - 72”W x 24”D x 74” H w/ 4
  shelves; no casters (Nexel)

  	
   

  	
  WQ188434

  	
   

  	
  8

  
	
  - Stem Casters 5: (set of
  4 casters; 2 vv/ brake) (Nexel)

  	
   

  	
  WQ500592

  	
   

  	
  8

  
	
  - Chrome Wire Shelf 72”W X
  24”D (Nexel)

  	
   

  	
  WBI 88564

  	
   

  	
  8

  
	
  Work Benches

  	
   

  	
   

  	
   

  	
   

  
	
  - Production Bench (tape,
  FedEx, etc.) 48” x 30” w12 shelves above

  	
   

  	
  W0606998

  	
   

  	
  2

  
	
  - Work Bench 12’L x 30”D x
  34”H (ea)

  	
   

  	
  WQ488020

  	
   

  	
  2

  
	
  Stackable containers (Akro-Mills) 11”W x 24”D x 4”H (pkg of 6)

  	
   

  	
  WB752367BL

  	
   

  	
  20

  
	
  Plastic Service Carts 401L x 26”W x 33”; 2 - shelves (ea)

  	
   

  	
  WB498526

  	
   

  	
  4

  
	
  RUBBERMAID Round Brute Container Dolly

  	
   

  	
  WM239003BK

  	
   

  	
  4

  
	
  44 GAL. Gray Brute Waste Container

  	
   

  	
  WM239007GY

  	
   

  	
  4

  
	
  Trash Can Liner Black 60 GALLON 1.5 MIL (100 ct)

  	
   

  	
  WM603564

  	
   

  	
  4

  
	
  7 STEP Easy Turn Rolling Ladder

  	
   

  	
  WM954790

  	
   

  	
  1

  
	
  Warehouse Dolly

  	
   

  	
  WM585283

  	
   

  	
  2

  
	
  Vertical File Letter 5 Drawer Gray w/ lock (signore)

  	
   

  	
  WM506582GY

  	
   

  	
  2

  
	
  Tape dispenser - handheld

  	
   

  	
  WB795451

  	
   

  	
  2

  
	
  Security Storage Truck 50”w x 24”d x 69”h

  	
   

  	
  NP334529

  	
   

  	
  1

  
	
  - 24” x 60” shelving for
  Security Storage Truck

  	
   

  	
  NP241296

  	
   

  	
  1

  
	
   

  	
   

  	
   

  	
   

  	
   

  
	
  JS Digital Scales - 2410
  Rocky Ford Rd, Newton NC 28658
  (877)464-5553

  
	
  My Weigh i101 (100g x 0.005g)

  	
   

  	
  SCM101

  	
   

  	
  1

  
	
  HP Products (Shipping Supplies) (314)770-2867 Acct # C009690

  
	
  30 oz. Foam Brick, 12/case, 75 cases to a skid

  	
   

  	
  131998

  	
   

  	
  2 skids

  
	
  Petite Blue Shipper pallet F

  	
   

  	
  132589

  	
   

  	
  1 skid

  
	
  Petite Blue Shipper pallet G

  	
   

  	
  132588

  	
   

  	
  1 skid

  
	
  Petite Blue Shipper pallet H

  	
   

  	
  132587

  	
   

  	
  1 skid

  
	
  Small Blue Shipper pallet A

  	
   

  	
  132586

  	
   

  	
  1 skid

  
	
  Small Blue Shipper pallet B

  	
   

  	
  132585

  	
   

  	
  1 skid

  
	
  Small Blue Shipper pallet C

  	
   

  	
  132584

  	
   

  	
  1 skid

  
	
  Small Blue Shipper pallet D

  	
   

  	
  132583

  	
   

  	
  1 skid

  
	
  Small Blue Shipper pallet E

  	
   

  	
  132582

  	
   

  	
  1 skid

  
	
  WATER ACTIVATED TAPE 72MMX45OFT REINFORCED

  	
   

  	
  120492

  	
   

  	
  1 cs

  
	
  BOX SEALING TAPE 2” X 100M

  	
   

  	
  116864

  	
   

  	
  1 cs

  
	
  F21013 BAG 10X13 2 MIL ELKAY CLEAR LINE POLY SINGLE TRACK

  	
   

  	
  102314

  	
   

  	
  3 bx

  

 

 

	
  Item Description

  	
   

  	
  Re-order
  number

  	
   

  	
  Quantity

  
	
  112” 48” X 250’ BUBBLE, S12, PERFORATED 12

  	
   

  	
  120546

  	
   

  	
  1 bdl

  
	
  STRETCH FILM 20XI000FT 80GA

  	
   

  	
  111384

  	
   

  	
  1 bx

  
	
  72MM X 375’ WHITE WATER ACTIVATED GUM TAPE

  	
   

  	
  120491

  	
   

  	
  1 cs

  
	
  24” X 36” NEWSPRINT, 50 LB. BUNDLE

  	
   

  	
  112507

  	
   

  	
  1 bdl

  
	
  40 x 46 2 mil heavy duty can liner

  	
   

  	
  112382

  	
   

  	
  1 bx

  

 

**NOTE:  Reference attached master patient supply
inventory list attached to Pharmacy Operations checklist**

 

 

Appendix L: Emergency Script/News Release

 

Emergency Script

Thank
you for calling [Program Name].
Due to an emergency situation outside of our control, our facility is not
accessible. We will be working from alternate sites. The contact phone numbers
will remain the same. Please leave your name and callback number. We will
return your call as soon as possible. We appreciate your patience while we work
to return to normal operations.

 

Disaster Plan Media Contacts

In
the event of a major business interruption or other adverse situation,
pro-actively reaching out to the local news media at the earliest possible time
is strongly recommended. Reaching the media first will help maintain balance in
the media’s coverage of such events, and will also establish CHR’s credibility
with the media throughout the course of events.

 

Before
contacting the media, however, be sure to contact the appropriate fire,
disaster response and emergency agencies in a timely manner. Not only is this
the right thing to do, but these agencies will likely be contacted by the news
media at some point for reporting and comment. Ensuring public safety first
will build credibility for CHR in the eyes of the media.

 

Second,
post a message on CHR’s website pertaining to the situation, and update it
regularly.

 

Then,
It is recommended that the following news media be contacted, in the following
order and utilizing the contact information below.

 

·                                          St. Louis
Post-Dispatch — News Hotline: 314-340-8222 or metro@post-dispatch.com

·                                          KMOX-AM - News
Tips: 314-444-3234, FAX 314-588-1234 or kmoxnews@kmox.com

·                                          KTRS-AM - News
line: 314-453-9774, FAX 314-453-9807 or newsAktrs.com

·                                          KWMU-FM News:
314-516-5968, FAX 314-516-6397 or news@kwmu.org

·                                          KSDK-TV News:
314-444-5126, FAX 314-444-5164 or newstips@ksdk.com

·                                          KMOV-TV News:
314-444-6333, FAX 314-444-4775 or tips@kmov.com

·                                          FOX2 KTVI-TV:
News: 314-644-7541, FAX 314-644-8960 or ktvinews@foxtv.com

·                                          KPLR-TV (CW11)
News: 314-447-6397, FAX 314-447-6430 or KPLRNews@tribune.com

·                                          St. Louis
Business Journal Web Editor/Daily News: 314-421-8381 or
matthewallen@bizjournals.com

 

It
is also recommended to make contact via e-mail, followed by a phone call.

 

 

Centric

health resources

 

Sample News Release

 

Contact

 

John
Fielder

Centric Health Resources

jfielder@centrichealthresources

562-480-3988

 

DRAFT

 

Centric Health Resources Implements Business
Continuity Plan In Response To (Disaster Event) That Affected Business Operations
On (Day/Date) In Chesterfield, Missouri.

 

Chesterfield, MO — (Date) — Centric Health
Resources has resumed normal business operations one day after (disaster event)
interrupted business operations at their headquarters facility. The (event)
forced the temporary suspension of all on-site distribution and communications
activities. After the initial damage assessment, the business continuity plan
was activated and all back-up locations were notified to go active immediately.

 

“Given
the severity of this (event) we’re very pleased that our emergency preparedness
efforts worked according to plan and that we were able to resume operations
within hours from our remote sites”, said Craig Kephart, president and CEO of
Centric Health Resources. “Our patients depend on us for the timely shipments
of their therapies and supplies and I’m proud to report that we encountered
only minimal disruptions despite this difficult situation,” he concluded.

 

About Centric Health Resources

Centric
health Resources, Inc. is a nationwide, patient centered health management®
organization, serving patients with rare, ultra-orphan diseases. Biotech and
pharmaceutical manufacturers maximize value by aligning with Centric for
streamlined coordination and direct delivery of specialty pharmaceuticals.
Centric connects physicians, nurses, health benefit payers, patient advocacy
groups, biotech/pharmaceutical companies and families together in partnership
for improved service and outcomes to these specialized patient populations.

 

Visit
www.centrichealthresources.com

 

 

Centric

health resources

 

Appendix M: Manual Forms

Table of
Contents

 

	
  1.

  	
  Centric Letterhead and Program Logos

  
	
  2.

  	
  Centric Fax Coversheet

  
	
  3.

  	
  Program Fax Coversheets

  
	
  4.

  	
  Home Health Agency Assessment Form, RD-2-09a

  
	
  5.

  	
  Nursing Services Contract & Authorization, RD-2-09b

  
	
  6.

  	
  Care Coordination Form, RD-2-09c

  
	
  7.

  	
  Patient Resource Guides,
  RD-3-01c-e

  
	
  8.

  	
  Patient Information Worksheet, RD-3-02a

  
	
  9.

  	
  Insurance Verification Form, RD-3-02b

  
	
  10.

  	
  Wholesale Intake Form

  
	
  11.

  	
  PSI Patient Referral Program/Forms

  
	
  12.

  	
  Initial Supply Requisition - Central Line

  
	
  13.

  	
  Initial Supply Requisition - Peripheral

  
	
  14.

  	
  Appeal Consent Letter, RD-4-01a

  
	
  15.

  	
  Physician Order Forms, RD-5-01 a-i

  
	
  16.

  	
  Prescription label

  
	
  17.

  	
  Manual Pick Ticket

  
	
  18.

  	
  Inventory Tracking Form, RD-5-07a

  
	
  19.

  	
  Health Insurance Claim Form (hardcopy only)

  
	
  20.

  	
  Payment Adjustment Form, RD-6-09a

  
	
  21.

  	
  Training Log Form

  
	
  22.

  	
  Request for Time Off Form

  
	
  23.

  	
  Employee Time Sheet

  
	
  24.

  	
  Directions - Hostirian, Foundation
  Care

  
	
  25.

  	
  Business Continuity Plan Checklist, RD-2-15e

  
	
  26.

  	
  Master Supply List

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]